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Matrix metalloproteinase (MMP)-responsive materials have been investigated since the 
late 1990’s as scaffolds for tissue engineering and since then, have evolved into sophisticated 
nanomaterials for cancer-targeting therapy. In this thesis titled, “Design and Application of Matrix 
Metalloproteinase-9-Responsive Peptide Nanostructures,” we aim to answer the following key 
questions: can MMP-responsive nanomaterials improve the efficacy of anti-cancer treatments? 
How can we achieve specificity towards MMPs using nanomaterials? Finally, what are the 
advantages in using peptides as building blocks to create MMP-responsive nanostructures? Each 
chapter in the thesis will address one or more of the key questions and draw conclusions at the 
end.  
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1.1. Introduction to thesis 
 Matrix metalloproteinase (MMP)-responsive materials have been investigated since the 
late 1990’s as scaffolds for tissue engineering and since then, have evolved into sophisticated 
nanomaterials popularly used for cancer-targeting therapy. In this thesis titled, “Design and 
application of matrix metalloproteinase-9-responsive peptide nanostructures,” we aim to answer 
the following key questions: can MMP-responsive nanomaterials improve the efficacy of anti-
cancer treatments? How can we achieve specificity towards MMPs using nanomaterials? Finally, 
what are the advantages in using peptides as building blocks to create MMP-responsive 
nanostructures? Each chapter in the thesis will address one or more of the key questions and draw 
conclusions at the end. 
 Chapter 2 will analyze literature examples to examine if MMP specificity can be better 
achieved using nanomaterials. The advantages and shortcomings of MMP-responsive 
nanomaterials in improving the efficacy of anti-cancer treatments will also be discussed. Chapter 
3 describes the synthesis and characterization of short peptides as building blocks to form MMP-
responsive nanostructures. A systematic design of the peptide sequence will be used to evaluate 
important parameters in achieving MMP specificity and to regulate nanostructure morphology and 
response kinetics. Chapter 4 will address a common challenge that reduces the reproducibility in 
peptide self-assembly (through residual TFA), and how to rectify it. The biocompatibility and bio 
application of MMP-responsive nanostructures will be examined in Chapter 5. Finally, the last 
chapter will summarize the findings of this thesis and discuss future prospects.   
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1.2. Hypothesis and specific aims 
 
Nanomedicines take advantage of particle size (1-500nm) and surface properties of 
nanoscale materials to accumulate selectively in the tumor microenvironment. Examples of FDA-
approved nanomedicines include Doxil (pegylated liposomal doxorubicin), Abraxane (albumin 
bound paclitaxel), and dozens more in clinical phase III trials. In addition to passive targeting, 
nanomedicine can be designed to actively target tumor cells using various endogenous stimuli such 
as pH, antigens, integrins, and enzymes that are characteristic of cancer cells. However, it is still a 
challenge to design nanostructures that can respond to cancer cell specific stimuli. Part of the 
challenge is the identification and realization of appropriate materials that can be fine-tuned to 
have the desired chemical and physical properties. Peptides have made a significant impact in 
biomedical applications due to their inherent biocompatibility and versatility in forming stable 
supramolecular nanostructures with desired functionalities, as well as their potential to be fully 
biodegradable (or metabolizable).  
Using systematic peptide design, my hypothesis is that the morphology, size, and charge 
of nanostructures can be customized to respond to MMP-9 with controlled response kinetics and 
mode of action for biological applications. The specific aims of my research project are: 
Aim 1: Systematic design and characterization of peptide nanostructures 
Aim 2: Control of MMP-9 responsive kinetics and mode of action  
Aim 3: Biocompatibility and application of peptide nanostructures using metallodrugs 
The primary sequence of peptide nanostructures is the key to achieving MMP specificity, attaining 






Literature analysis of MMP-Responsive Nanomaterials for Targeted Therapy  
 
Summary 
Matrix metalloproteinases (MMP) are enzymes that degrade extracellular proteins and 
multiple diseases, including cancer progression, are linked to their irregular overexpression and 
activity. Inhibiting the enzymes using small molecules has been a challenge due to the similar 
substrate binding sites of the MMPs and multiple roles they play during stages of cancer. Rather 
than inhibiting them, MMP-responsive nanomaterials take advantage of the enzyme 
overexpression and utilize MMP activity to trigger events that cause desired changes in the 
nanomaterials. The nanomaterials can act as drug-loaded nanocarriers and respond to MMP action 
to undergo different modes of responses including particle/micelle size shrinking, aggregation, and 
morphology switch from biocompatible nanomaterials to cytotoxic nanofibers. By analyzing over 
40 different systems described in the literature, we have formulated guiding principles in designing 
MMP-responsive nanomaterials to achieve MMP specificity. The key components include 
modification of the cleavable substrate and the supramolecular architecture and electrostatic 
charge of the nanomaterial. Finally, we review how the different modes of response effect the rate 










Matrix metalloproteinases (MMP) are a family of enzymes that are responsible for 
degrading components of the extracellular matrix and regulating extracellular cell signals for 
normal cell behaviors such as turnover of tissues, angiogenesis, wound healing, etc. Thus, irregular 
expression and activation of MMPs have been linked to multiple diseases including arthritis,1 
cardiovascular diseases,2 and cancer progression.3 Specifically, the upregulation of MMPs in many 
types of cancer have been studied in cell culture, animal models, and in patient-derived samples.4–
9 Therefore, MMPs have become a popular target for anti-cancer therapy, either directly by 
inhibiting MMP activity using small molecules, collagen peptidomimetics, etc. or indirectly by 
inhibiting MMP gene expression or MMP interaction with other proteins.10 However, many of 
these strategies have failed during clinical trials (Batimastat, Marimastat, CGS 27023A, 
Tanomastat, etc.) and MMPs remain as unattained, highly desirable targets.11 Major reasons for 
the failure include non-specific inhibition of the 21 different MMPs with similar substrate pockets 
and the timing of the MMP inhibition during cancer progression, which led to broad inhibition of 
MMPs, including the ones that have anti-cancer effects at specific stages of cancer.12,13 While this 
lack of specificity has led the big pharmaceutical companies to focus less on investigating MMP 
inhibitors, researchers continued to develop new and improved strategies to target MMPs to 
address these issues, including the use of MMP-responsive nanomaterials.  
A relatively new strategy in targeting MMP is to exploit the innate activity of the 
proteinases, instead of inhibiting it, to trigger anti-cancer effects using nanomaterials to release 
payloads (small or bio- molecule) or form cytotoxic nanofibers. This strategy could be more 
advantageous because the desired anti-cancer effect will, in theory, only be triggered in areas 
where MMP activity is upregulated during specific stages of cancer progression, which allows 
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temporal and spatial control of the nanomaterial response. In addition, the approach incorporates 
MMP substrates, and with good understanding of MMP specificity it can be optimized to be 
selective towards specific MMPs.  
The first MMP-responsive material was described by Jeffrey Hubbell in 1999, pertaining 
the production of polyethylene glycol (PEG)-based polymer hydrogels that contained crosslinks 
that could be degraded by MMP to enable cell migration.14 Specifically, the PEG-based polymers 
were crosslinked with MMP-1 cleavable peptide sequence and RGD motif to form a hydrogel that 
could be used as a 3D tissue scaffold, in which entrapped fibroblasts can proteolytically degrade 
the gel and invade outward.15 This MMP-responsive hydrogel was subsequentially modified to 
non-covalently incorporate bone morphogenetic proteins and implanted into defected rat cranium 
in vivo. Within 4 weeks, localized invasion of fibroblasts and complete bone regeneration of the 
defect was observed.16 Following Hubbell’s example, numerous types of MMP-degradable 
hydrogels have been described for stem cell and tissue engineering, and expanded the field to 
investigate nanomaterials to target MMP related diseases, including cancer.  
Since these early reports, MMP-responsive materials have been developed for other 
applications, including targeted delivery of small and biomolecular therapeutic agents, imaging, 
phototherapy, as well as sensors to detect and quantify MMP levels in vitro and in vivo. Using 
MMP-responsive materials, an ideal system could selectively engage with a specific MMP target 
at the tumor site and respond at a pre-defined rate (from few hours to multiple days) to have spatial 
and temporal control of the desired effect. This chapter will discuss the importance of targeting 
MMPs in anti-cancer therapy and analyze literature on MMP-responsive nanomaterials for anti-
cancer therapy. We will review different modes of MMP-triggered response that the nanomaterials 
can have and evaluate which properties of the nanomaterial such as composition, size, shape, 
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charge, etc. can influence MMP targeting by directly comparing the rate of peptide hydrolysis, or 
by indirect comparison in the rate of nanomaterial response such as changes in physical properties 
or release of payloads. Finally, we will analyze how both the mode and rate of MMP-response in 
nanomaterials can affect the targeting activity of the nanomaterial in vitro and in vivo, and 
ultimately draw conclusions on guiding principles to help create MMP targeting systems that are 
customized to specific needs and functionalities. 
 
2.2. Structure and functions of matrix metalloproteinases  
 
Matrix metalloproteinases, also called matrixins, are a family of zinc dependent 
endopeptidases that degrade the extracellular matrix and communicate extracellular cell signals. 
There is a total of 23 known MMPs found in humans which are either secreted from the cells or 
are bound to the surface membrane (called membrane type-MMP, MT-MMP).17 Traditionally, 
MMPs were grouped by their substrates, such as collagenases or gelatinases, but upon discovery 
of many more substrates they are now grouped together according to their domain structures 
represented in Figure 1 and are sequentially numbered. Regulation of MMP activity and expression 
at the transcription and translational levels are necessary and crucial for maintaining normal 
biological processes.18   
All MMPs are synthesized as inactive pro-peptides or zymogens and are activated 
extracellularly (except for furin-activated and secreted MMPs) when required through a “cysteine 
switch” process which breaks the Cys-Zn2+ interaction between the cysteine in the pro-peptide 
domain and the Zn2+ in the catalytic domain of the enzyme. Once activated, MMP activity is 
regulated by a class of proteins called tissue inhibitors of metalloproteinases (TIMPs) that can form 
a complex with the catalytic domain of MMP and inhibit MMP activity. Thus, the up- or down-
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regulation of MMP expression and activity have been linked with multiple diseases, including a 
wide variety of cancers. Detailed descriptions of the structures and functions of MMPs have been 
published widely by Hideaki Nagasse,17,18 and Table 1 summarizes the 23 human MMPs with their 
common names, domain structure, substrates, and biological roles. The isoelectric points (pI) of 
the MMPs are also listed which is relevant in designing electrostatically charged nanomaterials to 
match the enzyme’s charge (will be discussed in Section 2.3.3.).19 The membrane types are 
generally more basic, with pI values ranging from 5.96 to 9.70, compared to the secreted MMPs 
which range from 5.26 to 7.73 (except MMP-12 which has pI of 8.75).  
 
2.2.1. MMP overexpression in cancer 
 
The role of MMPs in cancer progression has been studied since the 1980’s and has been 
mainly associated with one of the six hallmarks of cancer, tissue invasion and metastasis.20 Since 
then many other cancer development processes have been associated to MMPs, including cancer 
cell invasion, proliferation, apoptosis, tumor angiogenesis and vasculogenesis, cell adhesion, 
migration, and epithelia to mesenchymal transitions, as well as escaping the immune 
surveillance.3,10 The regulation of MMPs is a complex biological process, and both down- or up- 
regulation of MMPs have been observed based on subtypes8 and stages9 of cancer. Of the different 
MMPs, MMP-2, -7, and -9 have been most widely studied for their overexpression during cancer 
progression.7 Table 2 lists concentrations of MMPs measured in various cancer cell lines, mice 
models, and patient derived samples quantified using ELISA or other fluorimetric assays. The 
concentrations vary by cancer types and samples, but in general they range around ng/ml for MMP-





Figure 2.1. Simplified representation of domain structures that are found in 5 secreted and 3 
membrane type MMPs. The pre domain guides the enzyme towards the endoplasmic reticulum, 
the pro domain keeps the catalytic domain inactive until needed, and the homopexin domain is 
connected to the catalytic domain by a hinge to mediate interaction with other proteins. 
Fibronectin-like domains can bind to collagen, furin domains can bind to serine proteinases to 
activate the enzyme, and some contain Vit = vitronectin like inserts. Membrane types contain 
TM = transmembrane domain and CT = cytoplasmic domain, or GPI = 
glycosylphosphatidylinositol anchoring domain, or SA = signal anchor, Cys = cysteine array, and 



















Table 2.2. (continued) 
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2.3. Achieving MMP specificity using nanomaterials 
 
MMP-responsive nanomaterials take advantage of the inherent overexpression and activity 
of MMPs produced by cells to trigger a desired response in the material. These responsive 
nanomaterials are made up of various building blocks, such as peptides,28,30–35 lipids,22,23,26,29,36–41 
polymers,14,24,42–54 naturally derived,55–59 and inorganic27,60–62 materials that have different 
chemical and physical properties. The versatility of MMP-responsive nanomaterials allow them to 
be used in any biological applications that involve overexpression and activity of MMPs, including 
regenerative medicine,30,31,55 targeted delivery of therapeutic21–24,27–29,32,36–41,46–48,50,52–54,56–59,62 or 
imaging agents,51,60,63–65 phototherapy,61,66 and diagnostic sensors.67–70 
The one shared key component in MMP-responsive nanomaterials is a peptide sequence 
that can be recognized and hydrolyzed by MMP and cause a physical or chemical change in the 
nanomaterial. This peptide sequence is often used as a linker to covalently link the building blocks 
together or may be a structural part of the material itself, in the case of self-assembled peptides. 
The MMP-cleavable sequence is typically at least 6 amino acids long in order to be recognized by 
the binding site of the enzyme and is modified on the C- and N-terminus to be imbedded or attached 
onto the building block. Because MMPs are highly specific enzymes, the design of MMP-
responsive materials needs to be considered thoroughly in many aspects beyond the cleavable 
substrate, such as the properties and functions of the nanomaterial.  
For MMPs to cleave the substrate, the enzyme must first interact with the nanomaterial and 
have access to the substrate before it can bind to it. Based on a simplified estimate of spherical 
proteins with similar molecular weight of MMPs, a 100 nm nanoparticle is about 30-50 times 
larger than the enzyme (radius of proteins with 10-100 kDa can be calculated 2.4- 3.05 nm).71 Thus 
the interaction of the enzyme with the nanomaterial is completely different from its interaction 
14 
 
with a monomeric peptide substrate. Therefore, both the properties of the nanomaterial and the 
primary sequence of the cleavable substrate must be designed to be compatible with the targeted 
MMP.  
To analyze which features of the MMP-responsive materials are most relevant, we have 
surveyed the literature and analyzed 41 different systems that have been published after 2010 and 
the early pioneering work published by Hubbell. Table 3 lists the different material compositions, 
forms, shapes, sizes (storage modulus for hydrogels), ζ-potentials, and primary sequences of the 
cleavable substrate and compares them to the rate of conversion, that is the rate in which the 
substrate in the nanomaterial is hydrolyzed by MMP. In Table 3, the rate of conversion is 
considered to be measured directly if the authors have provided evidence showing that the peptide 
substrate was cleaved over time by chromatogram or gel electrophoresis. It is considered to be an 
indirect measurement if the authors reported changes in the nanomaterial as a response to the MMP 
action over time, such as changes in size, rheology or weight % for gels, ζ-potential, or drug release 
profiles. This distinction is important because the rate and degree of the response in the 
nanomaterial does not always correlate with the rate or the amount of substrate cleaved by MMP. 
Lastly, measurements are considered to be relevant if the authors only showed the performance of 
the nanomaterial in vitro or in vivo. In addition, while most of the conversion rates are measured 
by incubating MMP with the nanomaterial, some rates are measured on the isolated cleavable 
substrate, which is not comparable since the substrate is in an entirely different molecular context 
(size, surface properties, etc.) when packaged into the nanomaterial. The molecular context of 
cleavable-substrate is an important factor to distinguish in comparing the different MMP-
responsive materials.  
15 
 
Through analyzing the rates of conversion with the properties of the nanomaterials, we 
have identified 3 key factors that can enhance the nanomaterial and enzyme interaction and 
specificity towards the targeted MMP as illustrated in Figure 2. First and foremost, the primary 
sequence of the substrate must be specific for the enzyme to recognize it and subtle changes in the 
amino acids or terminal modification of the primary sequence can alter the cleavage site. Second, 
the morphology of the nanostructure must allow MMPs to access the substrate, and the 
supramolecular organization of the substrate can also target specific MMPs. Lastly, by either 
matching or mis-matching electrostatic interactions, the short-range interaction between the 






Figure 2.2. Three key factors to achieve MMP specificity using nanomaterials. (1) Modification 
of the primary sequence can shift the cleavage site of the peptide and slow down the rate of 
hydrolysis.77,78 Based on the supramolecular structure31,33,56 (2) and electrostatic charge31,36 (3) of 
the nanomaterial, specificity towards different MMPs can be achieved: β-sheet fibers can be 
cleaved by MMP-13 (green) but not by MMP-9 (pink), and cationic nanoparticles are readily 






















Table 2.3. (continued) 
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2.3.1. Sequence specificity 
 
The amino acid residues in the MMP-cleavable substrate are labeled by the number of 
positions starting from the scissile bond (bond between P1 and P1’) and are labeled P1 through P6 
towards the N terminus, and P1’ through P6’ towards the C terminus. Understanding substrate 
specificity of this family of enzymes can elucidate the functions of specific MMPs,72 and help to 
design more specific inhibitors.73 According to MEROPS database, over 7,600 MMP-cleavable 
substrates have been observed and recorded.74 In addition to natural substrates, many engineered 
sequences have been identified using various high throughput techniques such as phage display,75 
oriented peptide library method,76 and proteomic identification of protease cleavage site (PICS).77   
Although MMPs are highly specific enzymes, the general consensus sequence found in the 
database are similar among MMPs, with Pro in P1, Gly in P3, and Leu in P1’ being the hallmark 
of MMP substrates. This could be partly due to a bias towards working with sequences that has 
already been tested and are copied by other researchers. A thorough examination by Overall et al. 
in 2015, revealed that of 112 P1-P1’ cleavages reported for MMP-1, -2, -3, -7, -8, -9, -12, -13, and 
-14 in MEROPS database, only 79 cleavages were unique, and only 5 sequences contained both 
Pro in P1 and Leu in P1’.77 The authors investigated the substrate specificity of MMPs using 
FRET-based peptides by conjugating a fluorophore, Mca (7-methoxycoumarin-4-acetic acid N-
succinimidyl ester), on the N terminus, and a quencher, Dpa (dipicrylamine), on the C terminal 
end of P1’ residue (Figure 2A). The MMP cleavage of the peptides was analyzed by measuring 
the recovered fluorescence of Mca over time (Figure 2B). In comparison to the general consensus 
PLG↓L peptide, PLN↓L was cleaved 2.5 times faster by MMP-1 and PAG↓L was cleaved 2 times 
faster by MMP-2 and 0.25 times faster by MMP-3 (Figure 2B). Clearly, beyond the general 




Figure 2.3. Investigation of substrate specificity of MMPs using FRET-based peptides. A) 
Chemical structure of the FRET-based peptides (Mca fluorophore and Dpa quencher). B) 
Recovered fluorescence of Mca over time. Adapted from ref 77. 
However, MMP-responsive nanomaterials require the enzyme to interact with the insoluble 
nanomaterial and not just the free peptide molecules. MMP-cleavable substrates are typically 
covalently modified on the C and the N terminus of the peptides to act as linkers for block-co-
polymers or they are used to attach functional moieties on the surface of the nanomaterial, like 
targeting ligands. This modification of the peptide can have significant impact on the enzyme 
recognition and hydrolysis of the cleavage site. The Bing Xu group has observed that covalent 
modifications with hydrophobic residues of peptides PLGLRSK and PLSLRSK on the N terminus 
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can shift the cleavage site and change the rate of hydrolysis by MMP-9.78 In this study the two 
sequences were systematically modified by adding one or two phenylalanine residues on the N 
terminus followed by capping the terminus with acetyl, fluorenylmethyloxycarbonyl (Fmoc), 
pyrene, or naphthalene group. They observed that the cleavage site of unmodified peptide 
(PLGL↓RSK) shifted to PL↓GLRSK with the addition of one or two Phe residues, both with and 
without the capping groups, and the rate of hydrolysis decreased with increasing hydrophobicity 
of the capping group (100% conversion for uncapped peptides, 60% conversion for naphthalene 
capped peptides, and 30% conversion for Fmoc capped peptides in 72 h). This shows that even a 
small modification of length and N terminal substitution can lead to different products and 
conversion rates. Therefore, certainly more than the primary sequence of the substrate needs to be 
considered in designing MMP-responsive materials.  
 
2.3.2. Supramolelcular specificity 
 
The family of MMPs can essentially degrade all components of the extracellular matrix, 
ranging from highly ordered proteins such as helical collagen fibers to smaller proteins such as 
fibronectin or gelatin (Table 1). Traditionally, MMPs were named after their common substrates 
for example, MMP-1, -8, and -13 are also called collagenase 1, 2, and 3, respectively, and MMP-
2 and -9 are called gelatinase A and B, respectively. As the names suggest, MMPs have different 
roles in tissue remodeling, which require them to have specific interaction with their substrates. 
For instance, MMP-2 and -9 has been reported to bind to native type I collagen but cannot cleave 
it until it is in the denatured gelatin form, whereas MMP-1 can easily digest the collagen fiber.79 
Therefore, in addition to the primary sequence, the topology or the supramolecular structure of the 




Figure 2.4. MMP-13-responsive β-hairpin peptide hydrogels. A) Cartoon representation and B) 
amino acid sequence of self-assembling β-hairpin nanofiber hydrogels. C) The β-hairpin peptide 
fibers are hydrolyzed by MMP-13 and not by MMP-3. The rate of hydrogel degradation is more 
dependent on the rigidity of the gel than the substrate sequence. Adapted from reference 31.   
 
This structural specificity was demonstrated by Schneider et al. using MMP-13 responsive 
β-hairpin peptide hydrogels (Figure 4A).31 These peptides contain two proline residues in the 
middle of repeating IKV units to create a bend for the β-hairpin structure, and the second proline 
was used to insert the MMP-cleavable substrate PTG↓X, where X = Leu, Ile, Phe, and Ala (Figure 
4B). When β-hairpin peptide hydrogels were incubated with 80 nM of MMP-13 for 14 days, 32-
65% hydrogel degradation was observed, whereas no degradation was observed when incubated 
with 40 or 400 nM of MMP-3 for 14 days (Figure 4C). Based on the sequence, both MMPs should 
be able to cleave PTG↓X, however, the densely packed β-hairpin peptide fibers in the hydrogel 
was only degraded by MMP-13 that naturally digests collagen fibers and not by MMP-3 which 
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digests sheet-like structures such as the collagen IV, perlecan, etc. in the basement membrane 
(Table 1). In addition, the rate of conversion in MMP-13 degradation of the hydrogel was also 
dependent on the structural topology of the gel. According to the sequence specificity, the expected 
rate of PTG↓X hydrolysis should have followed X = Leu > Ile, Phe > Ala. However, the observed 
order of degradation was X = Phe (65%) > Leu (58%) > Ile (44%) > Ala (32%), due to the low 
rigidity and larger pores of the Phe containing hydrogel which allows MMP-13 to penetrate gel 
faster (Figure 4C). This study shows that the morphology of the peptide fiber can be designed to 
target specific MMPs and the degree of crosslinks in the fiber network can be manipulated to 
control the rate of hydrogel degradation. 
A study by Ghandehari et al. demonstrated that the location of MMP-cleavable substrate 
in the nanostructure can also control the rate of degradation (Figure 5A).56 In this study, silk elastin 
polymers (silk-elastin-lysin elastin-silk motif) were modified with MMP-2 cleavable substrate 
(GPQGIFGQ) imbedded in 1) between the silk and elastin blocks, 2) within the elastin block, or 
3) within the silk block (Figure 5C). When a low concentration of 1 mg/ml of the MMP-responsive 
silk polymer was incubated in the soluble form with 40 nM of MMP-2, the three modified 
polymers were all digested 100% within 20-30 min. However, when 4% weight silk polymer 
hydrogel was incubated with 40 nM of MMP-2 for 14 days, different amount of digested and 
undigested polymers was released from the hydrogel (Figure 5B).  Higher ratio of digested vs. 
undigested released polymer was observed when the MMP-cleavable substrate was placed 
between the silk and the elastin blocks, followed by the substrate imbedded within the elastin 
block, and the substrate imbedded within the silk block had the lowest ratio of digested polymer. 
This is because the silk block (GAGAGS) is part of the major structural component, and the 




Figure 2.5. MMP-2-responsive silk elastin polymer hydrogels. A) Cartoon representation and B) 
amino acid sequence of self-assembling silk elastin nanofiber hydrogels. C) The placement of the 
MMP-2 cleavable sequence within the silk elastin polymer dictates the rate of hydrogel 
degradation. Adapted from ref 56.  
 
 The two previous examples by Schneider and Ghandehari groups altered the amino acid 
sequence and the placement of the cleavable substrate in the hydrogel to manipulate the rate of gel 
degradation and MMP specificity. Next, we discuss an example that will be discussed in detail in 
Chapter 3 to demonstrate that the morphology and the accessibility of the substrate in peptide 
nanostructures that do not gel can also be manipulated to control the rate of MMP hydrolysis.33 
Twelve amphiphilic peptides with diphenylalanine hydrophobic end and either lysine or aspartic 
acid containing hydrophilic end were systematically modified using MMP-9 cleavable PXG↓LXG 
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or AXG↓LXG motif in the center. The peptides were self-assembled at 1 mM and incubated with 
100 ng/ml of MMP-9 for 96 hours. We observed that among PXG↓LXG containing peptides, 
spherical micelles (100% in 48 h) were cleaved faster or at the rate as worm-like micelles (90% at 
96 h). In AXG↓LXG containing peptides, the higher rigidity of the peptide backbone contributed 
to higher ordered assemblies which slowed down the enzyme cleavage (from 60% to 10% in 96 
h), and MMP-9 was unable to digest peptides that formed anti-parallel β-sheet fibers.   
Using nanomaterials allow incorporation of more features, in addition to substrate 
specificity, to target specific MMPs and manipulate the rate of enzyme cleavage. By changing the 
amino acid sequence or the placement of MMP-cleavable substrate, the supramolecular structure 
and properties of the materials can be modified and play a large role in MMP specificity. 
 
2.3.2. Electrostatic specificity  
 
Electrostatic specificity may be one of the simplest ways to target enzymes but is often 
overlooked in meeting MMP specificity. The substrate binding pockets of MMPs are suited for 
hydrophobic interactions and the main focus has been on aromatic and aliphatic residues of the 
cleavable substrate. However, as emphasized in this literature analysis chapter, the short-range 
interaction of the MMP and the nanomaterial is as important as the sequence of the cleavable 
substrate. The electrostatic charge of the nanomaterials can be readily tuned to enhance or block 
enzyme engagement and can also be used to target specific MMPs. The isoelectric points (pI) of 
MMPs were computed by Rani et al. using ExPASy’s ProtParam tool and range broadly from 5.26 
to 9.94 (Table 1).19 In addition, the pI of MMPs can differ by isoform and charge variants. Using 
2D isoelectric focusing, Riccio et al. measured pI of 4.1-4.6 for several charge variants of 92 kDa 
pro-MMP-9 and 82 kDa activated MMP-9, and 6 different charge variants of 65 kDa MMP-9 with 
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pI ranging from 4.82-5.15.80 Using this information, the nanomaterials be designed to have same 
or opposite charge to repel or recruit specific MMPs, respectively, and to control the rate of enzyme 
cleavage. 
In our aforementioned work (Chapter 3), the 12 different MMP-9 responsive self-
assembling peptides were systematically modified to have either PXG↓LXG or AXG↓LXG motif 
and positive or negative charge using lysine or aspartic acid residues, respectively. As expected, 
the cationic peptides were readily cleaved by MMP-9 whereas the analogous anionic peptide had 
very low conversion (2.5% in 96 h) or were not cleaved at all. This was observed for both spherical 
and worm-like micelle peptide nanostructures. This electrostatic (mis) matching of charges 
between nanomaterial and MMPs is a simple yet powerful technique to enhance or prevent enzyme 
cleavage.  
In addition to the rate of MMP cleavage, electrostatic specificity can be utilized to target a 
specific MMP. Ahn et al. have designed a FRET-like system using gold nanorod particles coated 
with an MMP-cleavable substrate (GPLGVRGC) conjugated to Cy 5.5., a positively charged near-
infrared dye.61 The cleavage of the substrate was monitored by recovered fluorescence of Cy 5.5. 
dye. After 2-hour incubation period with different MMPs, the fluorescence was recovered 8.2 
times with MMP-9, 7.8 times incubated with MMP-2, 6.6 times with either MMP-3 or -13, and 
3.7 times with MMP-7. The authors recognized this selectivity but did not comment on the reasons 
underpinning it. Our speculation is that the electrostatic interaction of the modified cationic gold 
nanorods and the MMPs were favorable for anionic MMP-2, -3 -9, and -13 which have pI of 5.26 
- 5.77. On the other hand, the pI of MMP-7 is 7.73, which makes it almost neutral at physiological 
pH and least likely to be recruited by the cationic gold nanorod.  
29 
 
Using (mis) matching electrostatic interactions between the enzyme and the 
nanostructures, the enzyme cleavage rate and specificity can be controlled. In Table 3, there are 
nanomaterials with negative zeta potentials that are cleaved by MMP-2 characterized by 
Torchillini and Zhu groups, however, the rate of conversion was measured on the isolated 
cleavable substrate and not on the anionic nanomaterial, or was indirectly measured based on 
payload release. Therefore, these results cannot be quantitatively compared because the rate of 
substrate cleavage is different when isolated vs. as part of the nanomaterial (as discussed 
previously in section 2.3.2.) and does not equal to the rate of payload release. Before comparing 
the rate of payload release to the rate of nanomaterial response, we will first discuss the typical 
types of MMP-responsive changes that nanomaterials have.  
 
2.4. MMP-triggered modes of response for targeted anti-cancer therapy 
 
Inhibition of MMPs using small molecular compounds or macro biomolecules for anti-
cancer therapy has failed in the past mainly due to the similar substrate binding site of multiple 
MMPs as well as the varying expression of MMPs during various stages of cancer development.11-
13 Instead of inhibiting the MMP action, MMP-responsive nanomaterials are designed to take 
advantage of the inherent overexpression and activity of MMPs to trigger a response in the 
nanomaterial which allows spatial and temporal control of the anti-cancer activity. As discussed 
in the previous Section 2.2., nanomaterials provide a versatile platform to tune the specificity 
towards an individual MMP using modification of the MMP-cleavable substrate and the 
morphology and charge of the nanomaterials.  
In this section, 12 different MMP-responsive nanomaterials which were used for anti-
cancer therapy, are described have been categorized into 4 different modes of responses: 1) particle 
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shrinkage, 2) particle aggregation, 3) nanofiber formation, and 4) de-PEGylation of the 
nanomaterial (Figure 6 and Table 4). Following the nanomaterial’s response, the anti-cancer 
activity is achieved either by releasing therapeutic small molecules from bio-compatible 
nanocarriers, or by switching morphology into nanofibers which can themselves have a therapeutic 
effect. As we review the different categories, we will analyze how the different modes of response 
can affect the rate of payload release and influence the bio-activities in vitro and/or in vivo. 
 
 
Figure 2.6. MMP-triggered modes of response for anti-cancer therapy. As a response to MMP 
hydrolysis of the substrate in the nanomaterial, the nanomaterial can 1) shrink in size,27,52,59,60 2) 
aggregate,39,46,48 3) switch into cytotoxic nanofibers,26,28 or 4) reveal a functional moiety in the 
nanomaterial without changing in size.40,41,47   
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2.4.1. Size shrinking 
 
Nanomaterials that are 100-200 nm in size can have enhanced accumulation in the tumor 
microenvironment, but this accumulation is limited to the periphery edge of the tumor.81 It has 
been proposed that by using nanomaterials that can shrink into smaller particles or release small 
particles in response to MMP cleavage, it allows the shrunken 10-40 nm particles to penetrate the 
interstitial tumor space. Fukumura et al. have used this strategy and decorated the surface of gelatin 
nanoparticles with quantum dots to form 98 nm nanoparticles (Figure 7A).60 After incubating the 
particles with MMP-2, 90% quantum dots (10 nm) were released from the gelatin particles in 12 
hours (Figure 7B). When the MMP-responsive gelatin nanoparticles and comparable non-
responsive silica particles decorated with quantum dots were directly injected into tumors in vivo, 
the quantum dots released from the gelatin particle had diffused 300 µm from the injection site, 
whereas the quantum dots on the silica particle remained concentrated in the initial injection 
location (Figure 7C). This example demonstrated a proof-of-concept that the MMP-triggered 
release of quantum dots allowed deeper penetration into the solid tumor mass, which could 
potentially be replaced by 10 nm nanocarrier of cancer therapeutics.  
In another system, Kizilel et al. developed magnetic iron oxide particles coated with MMP-
cleavable acrylate-PEG polymer loaded with doxorubicin (Figure 8A).27 These 210 nm particles 
shrunk into 31 nm particles after 1 day of incubation with collagenase (bacterial equivalent of 
MMP) (Figure 8B). Interestingly, this size shrinkage did not trigger an increase in doxorubicin 
(DOX) release until day 3. At day 4, 60% of doxorubicin was released from the particles that were 
incubated with collagenase, in comparison to the 36% released without collagenase. Our 
speculation is that although the nanoparticle’s size was responsive to the enzymatic cleavage of 




enzyme substrate, likely because the drugs are still embedded in the polymer coating and continues 
to degrade in solution over time. The DOX-loaded MMP-responsive nanoparticles were 
internalized by HeLa cells 11 times more than non-responsive or bare iron oxide particles in vitro 
(Figure 8C). In addition, the drug-loaded nanoparticle displayed time-dependent activity in which 
it was less cytotoxic to HeLa cells than free doxorubicin at 24 and 48 h, but more cytotoxic at 72 
h incubation, in agreement with the release rate of DOX from the nanoparticle. The two examples 
by Kizilel et al. and Fukumura et al. demonstrated that MMP-triggered shrunken nanoparticles can 
have enhanced internalization by cells in vitro and penetration in solid tumors in vivo, in 
comparison to non-responsive (not shrunken) nanoparticles. 
 
 
Figure 2.7. MMP-2-responsive size shrinking gelatin nanoparticles. (A) Cartoon representation 
and (B) experimental measurement of 10 nm quantum dots being released from 100 nm gelatin 
nanoparticles upon incubation with MMP-2. (C) The quantum dots from MMP-responsive gelatin 
particles were able to penetrate throughout the solid tumor in vivo, whereas the quantum dots from 






Figure 2.8. MMP-responsive size shrinking magnetic iron oxide nanoparticles. (A) Cartoon 
representation and (B) experimental measurement of 200 nm polymer coated particles shrinking 
to 30 nm after incubation with collagenase. (C) Doxorubicin from dox-loaded MMP-responsive 
nanoparticles were internalized 11 times more than non-responsive particles. Scale bar 10 µm. 
Adapted from ref 27. 
 
2.4.2. Induced aggregation  
 
Nanomaterials can increase the accumulation in the tumor site as discussed in the previous 
section and can also increase retention of the material by preventing it from diffusing back into the 
bloodstream. In this strategy, 20-80 nm particles enter the periphery of the tumor and aggregate 
upon MMP action to stay immobilized around the tumor tissue. Gianneschi et al. have developed 
paclitaxel conjugated block-co-polymers using MMP-cleavable substrate (GPLG↓LAGGERDG) 
as linkers to form 20 nm spherical particles (Figure 9A-B).46 When the substrate was cleaved by 
MMP-12, the amphiphilic balance of the polymer is altered, 95% of particles aggregated into 400-
1000 nm in 4 hours (Figure 9C). When treated in vivo, the tumor growth inhibition of 15 mg/kg 




(Figure 9D), however, the systematic toxicity was much lower, and the maximum tolerated dose 
was 15 times higher than that of free paclitaxel (Figure 9E).  
 
 
Figure 2.9. MMP-12-induced aggregating polymer nanoparticles. (A) Cartoon representation and 
TEM images of (B) 20 nm particles aggregating into (C) 400-1000 nm aggregates upon MMP 
action. (D) Inhibition of tumor growth by paclitaxel-loaded MMP-responsive nanoparticle was 
lower than free paclitaxel but, (E) the systematic toxicity much lower than free paclitaxel. Adapted 
from ref 46.  
 
MMP-induced aggregating micelles were developed by Zhu et al. using liposomes 
conjugated to PEG via a MMP-2 cleavable linker (GPLGIAGQ) to encapsulate paclitaxel.39 After 
2 hour incubation period with collagenase, the initial 33 nm spherical liposomes aggregated into 
818 nm. In this system, hydrolysis of MMP-2 cleavable linker separates the lipid and the PEG 
building blocks causing the post-cleavage hydrophobic lipid to aggregate while the released 
hydrophilic PEG is solubilized. After 4-hour incubation period, 55% of the payload was released, 




loaded MMP-responsive liposomes were ten folds lower than free drug in paclitaxel-resistant cell 
lines, MDA-MB-231 and NCI/ADR-RES (5-6 µM vs. 45-34 µM) due to increased uptake of the 
drugs, but was higher in drug sensitive cell line, A549 (0.042 µM vs. 0.008 µM). In this system, 
the destabilization of the micelles induced increased paclitaxel release and was more cytotoxic to 
paclitaxel-resistant cells in vitro.  
 
2.4.3. Cytotoxic amyloid-like nanofibers 
 
Enzymatically triggered formation of cytotoxic nanofibers is an emerging field in anti-
cancer therapy. This mode of response is extensively researched by Bing Xu’s group that use 
phosphorylated precursors to form cytotoxic fibers upon dephosphorylation by alkaline 
phosphatases overexpressed in cancer cells.82 Likewise, MMP-responsive precursors can also form 
cytotoxic nanofibers upon MMP-cleavage. Maruyama et al. designed lipopeptides that can be 
cleaved by MMP-7 and form nanofibers with high gelation propensity as a response (Figure 
10A).26 The amphiphilic lipopeptides form 20 nm spherical micelles and when incubated with 
MMP-7, the lipid portion of the cleaved product self-assembles into fibers within 1 hour (Figure 
10B). These fibers caused selective toxicity to cells in vitro, that correlated with the amount of 
MMP-7 produced by the cancer cells and were non-toxic to normal cells with low concentrations 






Figure 2.10. MMP-7-triggered formation of cytotoxic lipopeptide nanofibers. (A) Cartoon 
representation and molecular structure of the lipopeptide that switch morphology from (B) 
spherical micelles to nanofibers upon MMP-7 hydrolysis (TEM images, scale bar left 50 µm; 
right 100 µm). (C) The cytotoxicity of the nanofibers increases in cell lines that have high 
concentrations of MMP-7. Adapted from ref 26.  
 
Our group has also demonstrated that MMP-9-triggered formation of nanofibers has anti-
cancer properties in vitro and in vivo.28 In this system, 200 nm spherical peptide micelles were 
used to co-assemble with doxorubicin and cleaved by MMP-9 to form cytotoxic nanofibers (Figure 
11A). In 96 hours, 60% of the peptide (GFFLGL↓DD) was cleaved by MMP-9 and formed bundles 
of fiber (Figure 11B). The co-assembled doxorubicin was more cytotoxic in vitro and inhibited 
tumor growth more than free doxorubicin in vivo. Remarkably, the peptide alone displayed similar 





Figure 2.11. MMP-9-triggered formation of doxorubicin-loaded peptide nanofibers. (A) Cartoon 
representation and molecular structure of the peptide micelles that form (B) fiber bundles upon 
MMP-9 hydrolysis (AFM images). (C) Tumor growth inhibition of peptide nanofibers (red) is 
comparable to free doxorubicin (yellow) and is significantly improved using the co-assembled 
drug-loaded peptide nanocarriers (orange). Adapted from ref 28. 
 
2.4.4. Activation by de-PEGylation 
 
Polyethylene glycol or PEG is a hydrophilic polymer block often used as a coating to 
solvate nanoparticles. In biological applications, it is popularly used as a “stealth” material because 
macrophages are less likely to detect nanomaterials that are coated in PEG. In previous examples, 
removal of PEG groups caused a change in the amphiphilic balance of the building blocks and 
caused the material to aggregate or revealed smaller inorganic particles beneath the PEG layer. In 
this category, unlike the example discussed above, the removal of PEG groups from the 
nanomaterials does not cause a dramatic change in the size of the nanomaterials. On the contrary, 




the nanomaterials to maintain their pre-designed features while revealing the functional ligands 
that were shielded by PEG.  
Zhu et al. have developed MMP-responsive polymer lipid conjugate building blocks using 
PEG and phophoethanolamine (PE) conjugated by MMP-cleavable linker (GPLG↓IAGQ) and/or 
a trans-activating transcriptional activator (TAT) peptide that can form paclitaxel-loaded micelles. 
Two paclitaxel-loaded MMP-responsive micelles were made using PEG2k-GPLG↓IAGQ-TAT-
PEG1k-PE or PEG2k-GPLG↓IAGQ-TAT-PE and incubated with 50 µg/ml collagenase IV. In 2 
hours, micelles made of PEG2k-GPLG↓IAGQ-TAT-PE aggregated from 58 nm to 998 nm, 
whereas micelles made of PEG2k-GPLG↓IAGQ-TAT-PEG1k-PE slightly increased in size from 93 
nm to 102 nm. In addition, the non-aggregating micelles did not show a significant increase in 
drug release (about 50% release with and without collagenase), whereas the aggregated micelles 
showed significant increase in paclitaxel release (80% in comparison to 50% without collagenase). 
In the first micelle, the cleavage of PEG2k -GPLG exposes the cell penetrating TAT peptide on the 
surface while maintaining the structural integrity of the micelle due to the additional PEG1k group 
in the remaining building block, IAGQ-TAT-PEG1k-PE. In the second micelle, only IAGQ-TAT-
PE is left, which disrupts the amphiphilic balance and the structural integrity of the micelle, 
resulting in increased release of paclitaxel and aggregation of the post-enzymatic product. The 
TAT activated and paclitaxel-loaded micelles were able to penetrate and reduce the size of 
NCI/ADR-RES (ovarian tumor) spheroids significantly more than the aggregating counter micelle 
and were retained longer in tumors of mice in vivo. 
Ge et al. developed block-co-polymer with poly-D, L lactide and PEG linked by MMP-2 
cleavable linker (PEG113-GPLG↓VRGDG-PDLLA100) that can encapsulate paclitaxel and form 62 




was cleaved in 25 hours observed by HPLC. Although the PEG113 layer was removed, the size of 
the particle remained the same at 65 nm. In addition, the MMP-2 cleavage of PEG did not trigger 
release of paclitaxel. At 72 hours, 80% of paclitaxel was released from the micelle with and without 
incubation with MMP-2. When the PEG113 is cleaved from this micelle, the PDLA100 core remains 
conjugated to VRGDG which is surprisingly sufficiently hydrophilic to keep the particles from 
aggregating. The drugs remain within the core of the micelle and are unaffected by the MMP-2 
triggered cleavage of PEG113. The paclitaxel-loaded MMP-activated polymer micelle was more 
cytotoxic to 4T1 cells (breast tumor) in vitro and was able to inhibit tumor growth significantly in 
H22 tumor (hepatic carcinoma) bearing mice in comparison to free paclitaxel in vivo. The two 
examples by Ge and Zhu, and one more in Table 4, show that de-PEGylation of these micelles 
does not cause morphology change in the nanoparticle nor induce drug release and the anti-cancer 
efficacy of the treatments are increased.  
 
2.5. Summary and future directions 
 
In this chapter, we analyzed MMP-responsive nanomaterials and drew conclusions on 
guiding principles to design nanomaterials with specificity and functionality. First, the hydrolysis 
rate of MMP-cleavable peptide can be tuned by modifying the peptide substrate or the morphology 
and electrostatic charge of the nanomaterial that hosts it. Specificity towards a specific MMP can 
also be tuned by these methods. Second, the rate of payload release can be controlled by choosing 
the mode of response in the nanomaterial after MMP action. In general, the rate of MMP-induced 
payload release is delayed from the nanomaterial response. Third, the mode of response can have 
different advantages in the biological context. Size shrinking particles can penetrate deeper into 




toxicity in vitro and enhance the efficacy of drugs in vivo, and activated nanoparticles can reveal 
targeting ligands without inducing payload release or morphological change. The two examples of 
aggregating particles did not always increase the efficacy of the drugs, however, the overall 
systematic toxicity was lowered in vivo, and increased efficacy was observed in drug-resistant cell 
lines. Currently, the efficacy of anti-cancer treatments is measured by the ability to kill cells and 
reduce tumor size. However, as observed in this chapter, MMP-responsive systems do not always 
increase the toxicity nor tumor reducing ability of the payloads. Instead, the system achieves more 
selective and targeted therapy which could potentially reduce adverse side effects and transform 
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Chapter 3  
Customizing Morphology, Size, and Response Kinetics of Matrix Metalloproteinase-Responsive 
Nanostructures by Systematic Peptide Design 
 
Summary 
Over-expression and activation of matrix metalloproteinase-9 (MMP-9) is associated with 
multiple diseases, and can serve as a stimulus to activate nanomaterials for sensing and controlled 
release. In order to achieve autonomous therapeutics with improved space-time targeting 
capabilities, several features need to be considered beyond the introduction of an enzyme-
cleavable linker into a nanostructure. We introduce guiding principles for a customizable platform 
using supramolecular peptide nanostructures with three modular components to achieve tunable 
kinetics and morphology changes upon MMP-9 exposure. This approach enables: (1) fine-tuning 
of kinetics through introduction of ordered/disordered structures, (2) a 12-fold variation in 
hydrolysis rates achieved by electrostatic (mis) matching of particle and enzyme charge, and (3) 
selection of enzymatic reaction products that are either cell-killing nanofibers or that disintegrate. 
These guiding principles, which can be rationalized and involve exchange of just a few amino 
acids, enable systematic customization of enzyme-responsive peptide nanostructures for general 














Nanomaterials impact biomedicine by taking advantage of their inherent chemical and 
physical properties to achieve increased circulation lifetime and selective bio-distribution in vivo, 
and dictate cellular uptake mechanisms,1 all of which cannot be attained by molecular drugs alone. 
Another beneficial feature of nanomaterials is the ability to incorporate stimuli-responsive 
functionalities to enhance selectivity in targeting diseased cells, and manipulate drug release 
profiles.2–5 In particular, an inherent biological stimulus such as (over-) expression of enzymes, 
can serve as a marker for diseased cells, as well as a trigger to facilitate desired changes in the 
nanostructure.6 Understanding the relationship between properties of nanomaterials, such as size, 
shape, and charge, with their bio-distribution or cellular uptake patterns have allowed researchers 
to develop refined systems to target specific organs and cells. For example, Discher et al. described 
that the increase in length of flexible filomicelles up to 8 m increased the circulation lifetime in 
vivo in mice, in comparison to shorter filomicelles and spherical vesicles.7 Likewise, a thorough 
investigation is necessary in order to develop design rules for nanomaterials that can engage with 
the enzymatic stimuli with varying degrees of affinity in order to predetermine response kinetics 
for the desired enzyme-responsive action (i.e. disassembly, morphology switch, etc.).6  
For instance, an over-expression and activation of matrix metalloproteinase-9 (MMP-9), 
an enzyme that is crucial to normal behavior of cells such as degradation of extracellular matrix,8 
is associated with multiple diseases including cancer metastasis,9 cardiovascular diseases,10 
arthritis,11 etc. Since the introduction of polymeric MMP-responsive materials by Hubbell et 
al.,12,13 there have been numerous strategies to exploit this highly disease-relevant enzyme for bio-
medical applications.14–21 One of the challenges in designing MMP-9 responsive nanomaterials is 




with the nanoparticle system. Another, largely overlooked but important aspect of particle design 
is regulating the susceptibility of the nanoparticle to the enzyme stimuli through the manipulation 
of electrostatic properties of nanoparticles to attract or repel enzymes of opposite or same charge,23 
and to control the degree of supramolecular organization of the nanoparticle to increase or limit 
enzyme access to the particle, and ultimately influence the observed reaction and response 
kinetics.24 
A further design aspect is the morphology of the particle pre- and post-cleavage; there is 
increasing evidence that enzymatically triggered formation of nanofibers on tumor cells can cause 
cytotoxic effects,14,25 and Xu et al. have extensively studied this mechanism to overcome drug-
resistance in cancer cells,26,27 while disintegrating particles may be beneficial for controlled drug 
release.19,20  The anti-cancer activity of the nanofibers depends on the kinetics of fiber formation 
which in turn depend on the interaction between the enzyme and the precursor, as well as the self-
assembling ability of the post-enzymatic product.28 By employing these strategies, the response 
behavior of the enzyme-responsive nanomaterials can be optimized to achieve selective and 
controlled rates of drug release, and to introduce additional therapeutic functionalities.  
Thus, by using rational design of peptide sequences, we present here a modular platform 
to customize surface charge, supramolecular organization, and enzyme specificity of peptide 
nanostructures. We demonstrate the significance of these properties in showing that simple, few 
amino acid replacements can systematically control enzyme engagement and susceptibility to the 
enzymatic action. This further dictates the response kinetics and the action of the nanostructures 






3.2. Rational design of peptide sequences 
 
For this study, we designed self-assembling peptide amphiphiles29 that form stable 
nanostructures under physiological conditions, and undergo morphological change or degradation 
upon MMP-9 hydrolysis of the peptides. This study is based on our previous work which 
demonstrated that peptide micelles can encapsulate doxorubicin and transform into fibrous drug 
depots upon MMP-9 action.15,30 Thus, we created a modular system in which the peptide sequences 
contain three segments: (1) cationic or anionic hydrophilic segment to modulate enzyme 
engagement, (2) MMP-9 cleavable segment with ordered or disordered regions to influence 
enzyme kinetics and predetermine self-assembly or dis-assembly of post-cleavage product and, 
and (3) hydrophobic segment to drive self-assembly of precursor and of post-enzymatic self-
assembling product (with potential to bind hydrophobic drugs)15 (Figure 1). 
To demonstrate the ability to electrostatically recruit MMP-9 (pI = 5.7, net negative charge 
in physiological pH)31 to the peptide particles, we designed a hydrophilic segment in the peptide 
amphiphiles with cationic or anionic C termini. Each peptide was given a positive (1-3 AK/PK) 
or negative (1-3 AD/PD) charge using two lysine or two aspartic acid residues, thus creating 12 
sequences (Table 1). In addition, these surface charges increase solubility of the peptide 
nanostructures and can be customized to potentially influence cellular uptake and bio-distribution. 
To achieve MMP-9 specificity, and to program the distinct morphologies of the peptide 
nanostructures and the resulting enzymatic products, we designed the cleavable segment based on 
data from the MEROPS database,32 which suggests PX1GLX2G, where  represents the scissile 
bond, and X1 and X2 represent positions where there are no significant preferences for a single 
amino acid. The amino acid positions are designated starting from the scissile bond (red dash line 




terminal. Peptides 1-3 PK/PD contain Pro in P3 which is prevalent in substrates of most MMPs,
22 
however, Pro is known to disrupt assembly of secondary structures like -helices and -sheets in 
proteins.33 Therefore, in order to promote fiber formation of the post-cleavage enzymatic products, 
we substituted Pro for Ala in P3 in 1-3 AK/AD which is also found in natural substrates of MMP-
9.34 In addition, we varied P2 with small aliphatic residues to observe differences in enzyme 
specificity, and inserted Gly in P4 to change the self-assembling behavior of peptides and observe 
the consequent changes in enzyme kinetics. 
 
Table 3.1. Single letter code of 12 peptides before MMP-hydrolysis where the red dash line 






Figure 3.1. Cartoon of sequence dependent peptide nanostructures. (A) Chemical structure and 
(B) cartoon of self-assembling peptide amphiphiles that respond to MMP-9 action. Positive (blue) 
or negative (red) charges on the nanoparticle electrostatically recruit or repel MMP-9 to influence 
enzyme kinetics. Self-assembling (purple) and MMP-9 cleavable segments (gray and/or orange) 
dictate the susceptibility of the nanostructures to MMP-9 hydrolysis by forming 
ordered/disordered structures, and control the fiber formation or disassembly of the post-enzymatic 
products. Red dash line indicates the scissile bond.  
 
Lastly, to introduce the hydrophobic segment of our amphiphilic peptides, we used the 
well-known self-assembling sequence diphenylalanine35,36 on the first two positions of the N 
termini to drive self-assembly of nanostructures prior to enzyme action via hydrophobic and 
aromatic interactions, and to form nanofibers in a subset of sequences after enzyme action (1-3 
AK/AD). These 12 sequences represent a modular design in which the rate and morphology of the 




3.3. Characterization of the pre-enzymatic peptide nanostructures 
 
The 12 pre-enzymatic (1-3 AK/AD and 1-3 PK/PD) and 6 post-enzymatic (1-3 A and 1-3 
P) peptide sequences were synthesized using Fmoc-based solid phase peptide synthesis (SPPS), 
purified on a preparatory high-performance liquid chromatography (HPLC) using C18 column, 
lyophilized in water, and identified by high resolution liquid chromatography-mass spectrometry 
(HRMS) and 1H nuclear magnetic resonance (NMR) spectroscopy. The self-assembly of peptide 
nanostructures was investigated using CAC, FTIR, and ζ-potential, and finally the morphology of 
the nanostructures was imaged using AFM and TEM.  
The CAC values for the 12 precursor peptides were determined using pyrene as a 
solvachromatic fluorophore in PBS (pH 7.4) and are listed in Table 2. In general, the cationic 
peptides had the lowest CAC of 0.3 mM and 0.4 mM for 1-2 PK and 1-2 AK, respectively, except 
for 3 PK and 3 AK which aggregated at 0.7 mM and 0.8 mM, respectively. While the CAC of PK 
peptides were lower than its analogous AK peptides, no clear trend was observed for the anionic 
peptides. On the contrary to the cationic peptides, which had the highest CAC for 3 AK and 3 PK, 
the counter peptides 3 AD and 3 PD had the lowest CAC of 0.5 mM among the anionic peptides.  
According to clogP values predicted using Chemdraw, the cationic peptides are more hydrophobic 
(higher clogP) than the anionic peptides and have overall lower CAC than anionic peptides. In 
addition, the cationic peptides show a positive correlation of larger CAC values for lower cLogP 
values (more hydrophilic peptides) (Figure 2). However, for the anionic peptides larger CAC 







Table 3.2. Critical aggregation concentrations of peptides determined using pyrene (Figure S25-









The ζ-potentials of the peptide assemblies confirmed the presence of the expected positive 
or negative charges and the average ζ-potential values for the 12 precursor peptide nanostructures 
are listed in Table 3. Higher zeta potentials were observed for the anionic peptides which have 
negatively charged Asp residues on the free carboxyl termini of the peptides, in comparison to the 
cationic peptides in which the positive charge of Lys residues is negated by the free C termini. We 
note that measurements were made at high concentrations (5 mM) due to the limited light 
scattering properties of the peptide particles that may have contributed to aggregation which results 
in overall lower zeta potential values. 
Table 3.3. ζ-potentials of 5 mM peptides in 2% PBS (pH 7.4) at 25C (Figure S27-32). 
 
Analysis of Fourier-transform infrared spectroscopy (FTIR) spectra reveal that the self-
assembly of most of the peptide sequences are not majorly driven by highly ordered hydrogen 
bonding of the peptide backbones. Instead, the major peaks in the amide I region absorb between 
1640-1650 cm-1, indicative of disordered hydrogen bonds (shaded green in Figure 3C-D).37 Thus, 
the major contribution in the self-assembly of  1-3 PK/PD and 2-3 AK/AD is driven by the 
formation of diphenylalanine hydrophobic core solubilized by the hydrophilic lysine or aspartic 





Figure 3.3. AFM images and FTIR spectra of self-assembled peptide nanostructures. A-B) 1 
AK/AD form large fibers organized in anti-parallel -sheet arrangement, 2-3 AK/AD and 1 
PK/PD form elongated worm-like micelles, and 2-3 PK/PD form spherical micelles. Scale bar 
500 nm. Additional AFM images can be found in Figure S33-34. C-D) FTIR spectra of the peptides 
in amide I region. Red shade highlights the carboxylate groups (1580-1590 cm-1) which can red 
shift to lower wavenumber (1541 cm-1 for 1 AD) upon cation complexation,39 blue shade highlights 
parallel -sheet (near 1620 cm-1) and anti-parallel -sheet (additional peak at1688 cm-1) hydrogen 
bonding of the peptide backbones, and the green shade highlights disordered hydrogen bonds 




Atomic force microscopy (AFM) images show that AK/AD sequences form one-
dimensional nanostructures and PK/PD sequences form spherical nanostructures with the 
exception of 1 PK/PD (Figure 3A-B). Analysis of Fourier-transform infrared spectroscopy (FTIR) 
spectra reveals that the self-assembly of most of the peptide sequences are not majorly driven by 
highly ordered hydrogen bonding of the peptide backbones. Instead, the major peaks in the amide 
I region absorb between 1640-1650 cm-1, indicative of disordered hydrogen bonds (shaded green 
in Figure 3C-D).37 Thus, the major contribution in the formation of these spherical micelles (2-3 
PK/PD) or worm-like micelles (1 PK/PD and 2-3 AK/AD) are driven by the formation of 
diphenylalanine hydrophobic core solubilized by the hydrophilic lysine or aspartic acid tail.38 In 
contrast, 1 AK/AD show prominent characteristics of anti-parallel -sheet arrangement of the 
peptide backbone which absorbs at 1620 and 1687 cm-1 for 1 AK and at 1623 and 1696 cm-1 for 1 
AD (shaded blue in Figure 3C-D).  In addition, the carboxylate peak, which absorbs in 1580-1590 
cm-1 (shaded red in Figure 3C-D), is red shifted to 1541 cm-1 in 1 AD. This is indicative of cation 
complexation which suggests intermolecular salt bridge formation between the C and N terminal 
(or aspartic acid residues next to the C terminal) that contributes to the long-range order of the 
peptide assembly.39 We speculate that these highly ordered nanofibers are caused by the assembly 
of linear and rigid backbone of 1 AK/AD in P6-P1 (FFALG), and this is clearly evident in 1 PK/PD 
in which a single amino acid substitution of Ala to Pro in P3 (FFPLG) creates a kink in the peptide 
backbone and significantly disrupts the anti-parallel -sheet formation. Furthermore, the addition 
of Gly in P4 (FFGAX1G) in 2-3 AK/AD adds flexibility to the peptide backbone
40 which hinders 






3.4. Controlling enzyme kinetics 
 
Next, we measured the rate of MMP-9 cleavage of the 12 peptides. Lyophilized peptides 
were dissolved in phosphate-buffered saline (PBS) supplemented with 1 mM CaCl2 and 55 M 
ZnCl2 to be compatible with MMP-9 (a metalloproteinase with zinc and calcium dependent 
catalytic domain), the pH adjusted to 7.4, and sonicated for 10 mins to achieve 1 mM of peptide 
solutions. 100 ng/mL MMP-9 was incubated with peptides at 37C and the reaction was monitored 
up to 96 h using LC-MS to identify and quantify the enzymatic products by calculating the area of 
the product peak over the initial peptide peak (Figure S35-46).  
 
3.4.1. Electrostatic recruitment or repulsion of MMP-9 
 
Comparing the P1P1’ enzymatic products, the cationic peptides (Figure 4A) were 
preferentially cleaved by (anionic) MMP-9. For example, 2 PK had a 12-fold higher conversion 
in comparison to 2 PD (Figure 4B). This stark difference resulting from preferential hydrolysis of 
nanostructures by oppositely charged enzymes has also been observed by Wooley et al.24 using 
polymeric micelles.  
Interestingly, the major cleavage site for the cationic peptides was between GL in P1P1’ 
as anticipated, whereas the major cleavage site for the anionic peptides was between FF in P6P5 
with inconsistent results between two separate trials (Table S2). It has been reported that MMP-9 
cleavage site in peptides of similar length can shift to P2P1 or P1’P2’,
41 but this drastic shift to 
P6P5 suggests that the anionic peptides do not meet MMP-9 specificity. By electrostatic (mis) 






Figure 3.4. 1 mM of (A) 1-3 AK/PK and (B) 1-3 AD/PD incubated with 100 ng/mL of MMP-9 
at 37C. Peptides with Pro in P3 are marked grey, and Ala with orange. Average % conversion of 
peptides to the post-enzymatic products (P1P1’) from two separate trials. 1-3 PK showed the 
highest conversion and further degradation of the post-enzymatic product was observed for 2 PK 
(blue dash line). Over 50% of 2 AK was cleaved, while less than 10% of 3 AK and 1-2 PD was 
converted, and the rest were not responsive to MMP-9.    
 
3.4.2. Increasing or limiting accessibility to enzymatic hydrolysis 
 
In addition to the dramatically different conversion rates (and cleavage sites) resulting from 
electrostatic interactions, we can further fine-tune the rate of enzymatic hydrolysis by achieving 
enzyme specificity and by controlling the degree of order in the supramolecular peptide 
nanostructures. Of the cationic peptides, sequences with Pro in P3 (1-3 PK) were almost 
completely digested by MMP-9 within 96 h. In particular, 1 PK, which forms the smallest micelles 
of the three, was completely converted to the enzymatic product, FFPLG, in 48 h, and continued 
to be further hydrolyzed between FF (dash blue line in Figure 4A). This demonstrates the 
biodegradability of peptide nanoparticles, which may be useful for applications where (di) 




to completion at a similar rate due to the preferred Pro residue in P3, and the subtle differences in 
the peptide sequences did not affect the enzymatic hydrolysis rates.  
In the case of 1-3 AK, significant differences were observed due to the degree of 
supramolecular organization of the nanostructures. 3 AK, which has the highest CAC value of 
0.8mM, had a low conversion (below 10% by 96 h), whereas, 2 AK with a lower CAC value of 
0.4 mM had the highest conversion (up to 60% by 96 h), and no cleavage was observed for 1 AK 
(CAC value 0.4 mM). These data suggest that the kinetics of the enzyme hydrolysis are determined 
by the supramolecular order of the peptide assemblies rather than the hydrolysis of unassembled 
peptide monomers. The slight difference of introducing a glycine residue in the sequences of 2 AK 
and 1 AK (between diphenylalanine and alanine) contributes to a major change in the morphology 
of the two nanostructures. 2 AK, which has a more flexible peptide backbone due to the insertion 
of Gly residue in P4, forms disordered hydrogen bonds (Figure 3C) that leads to the formation of 
smaller fibrils (Figure 3A and Figure S33) and is susceptible to MMP-9 hydrolysis. However, 
without the Gly residue, the rigid peptide backbone of 1 AK in P6-P1 arranges in an anti-parallel 
-sheet configuration (Figure 3C) and form fibers that are microns in length (Figure 3A and Figure 
S33). These highly organized fibers are less susceptible to enzyme degradation, especially for the 
endopeptidase MMP-9, which has been observed to bind to type I fibril collagen, a large extra 
cellular matrix component, but cannot digest it until it is in the denatured, gelatin form.43 
Concluding from this set of 12 peptides, it is clear that we can dramatically control the rate and 







3.5. Characterization of post-enzymatic peptide nanostructures 
 
The hydrophobic N terminal fragments of the resulting enzymatic products (herein referred 
as 1-3 A/P) by SPPS and characterized using HRMS, 1H NMR, AFM, and FTIR. Controlling the 
morphology of the post-enzymatic products is important in designing MMP-responsive 
nanomaterials. For instance, enzyme-triggered fibers which form on or near the cell surface of 
cancer cells that produce the enzyme stimuli are known to be cytotoxic to the cells,44 and 
disassembling nanocarriers can be used for burst release of payloads. Distinct differences can be 
observed by peptides with Ala in P3 (1-3 A) which formed ordered structures, and peptides with 
Pro in P3 (1-3 P) which was expected not to self-assemble due to the Pro disrupting formation of 
ordered hydrogen bonds. FTIR spectra of the non-assembling peptides (Figure 5B gray lines) show 
absorptions at 1641, 1643 and 1653 cm-1 for 1 P, 2 P and 3 P, respectively, which is observed for 
amides of peptide backbones with disordered hydrogen bonds. A mixture of parallel -sheet (1628 
cm-1) and disordered (1643 cm-1) hydrogen bonds were observed for 2 A. In contrast, 1 A absorbs 
at 1627 and 1687 cm-1, and 3 A absorbs at 1624 and 1688 cm-1, which are distinct characteristic 
peaks of anti-parallel -sheet hydrogen bonds (Figure 5B orange lines). AFM images (Figure 5A) 











Figure 3.5. AFM and FTIR of synthesized post-enzymatic products. (A) AFM image of 1-3 A 
(top panel, left to right) and 1-3 P (bottom panel, left to right). Scale bar 500 nm. (B) FTIR spectra 
of 1-3 A in orange and 1-3 P in gray lines.   
 
3.5.1. Enzymatically formed fibers have higher order assembly 
 The morphology of the enzymatic products of 2 AK and 2 PK incubated with MMP-9 was 
monitored over time by FTIR and AFM. In addition to identifying and quantifying the post-
enzymatic products of peptides after incubation with MMP-9 (Figure 4), the morphology of the 
reaction product was also monitored over time for 2 AK and 2 PK by FTIR and AFM. Figure 6B 
shows that the disordered region of 2 AK (black line) disappears by 24 h and a sharp peak is 
observed in the 1620 cm-1 region indicative of ordered β-sheet hydrogen bonds (purple line). By 
48 h, an additional peak at 1680 cm-1 region can be observed which indicates the peptides are 
arranged in an anti-parallel β-sheet manner (pink line). In comparison, the synthesized 2 A, 
although identical in chemical composition (FFGALG), has a completely different absorbance and 
less order than the MMP-9 induced assembly. The AFM image of 2 AK after 24 h incubation with 




the FTIR of 2 PK does not change after incubation with MMP-9 or in comparison to the 
synthesized 2 P (Figure 6D). However, the AFM images of 2 PK prior to incubation with MMP-
9 show formation of uniformly spherical micelles about 50 nm in diameter (Figure 3A). The 
synthesized 2 P and the enzymatically formed 2 P both show small random aggregates, which 
confirms the lack of ordered hydrogen bond absorbance by FTIR. 
 
Figure 3.6. AFM images of 2 AK at 24hr (A) and 2 PK at 24hr (B), scale bar 500nm. (C) FTIR 
absorbance of 2 AK: 0 h, 24 h, 48h (0%, 24%, and 24% enzymatic products, respectively) and 2 
A for comparison. (D) FTIR absorbance of 2 PK: 0 h, 24 h, 48h (0%, 86%, and 91% enzymatic 
products, respectively) and 2 P for comparison. 
 
3.6. Biocompatibility of peptide nanostructures in vitro 
 
Moving forward, we chose to test the biocompatibility of the two peptides that were active 
against MMP-9, 2 AK and 3 AK, and their Pro analogous peptides 2 PK and 3 PK. We chose a 
human clear cell renal cell carcinoma line, Caki-1, because tissues from patients with this type of 
kidney cancer show significantly higher expression of MMP-9 mRNA, with increasingly higher 




fibroblast cell line, IMR90, which was reported to have negligible expression of MMP-9 mRNA.46 
1 mM of the peptides were incubated with Caki-1 and IMR90 cells at 37C for 72hrs and the cell 
viability was determined using the Presto Blue assay (Figure 3.7. A-B). The peptides are non-toxic 
to both cell lines with cell viabilities over 90%, except for 3 AK which forms -sheet fiber post-
cleavage and decreased the cell viability of Caki-1 cells to 66%, despite the observed low 
conversion (Figure 4A). 
 
Figure 3.7. Biocompatibility of peptide nanostructures. Cell viability of human renal cancer cell 
line, Caki-1, with high expression of MMP-9 (A), and non-cancerous human fibroblast, IMR90, 
with normal expression of the enzyme (B), incubated with 1 mM peptides for 72 hrs. The peptides 
are non-toxic to both cell lines, except for 3 AK which decreased the cell viability of Caki-1 to 
66%. (C) FTIR spectra of the post-cleavage peptides show that only 3 A forms anti-parallel -
sheet peptide fibers which causes the cytotoxic effects in Caki-1 only. (D) TEM images of 3 AK 




enzymatic products, 3 A and 2 P which form rigid fibers or random aggregates, respectively. Scale 
bar 100nm.  
 
3.6.1. Nanofibers induce selective toxicity in cancer cells 
 
In order to understand the effects of the post-cleavage products in vitro, we examined the 
hydrophobic N terminal fragments of the resulting enzymatic products characterized in section 
4.5. In comparison to 2 P and 3 P, which form random aggregates, 2 A formed short fibers and 3 
A formed large fiber bundles (Figure 5A). TEM images (Figure 7D) show that the precursor 2 PK 
forms spherical particles which, when converted to 2 P, disassemble and remain as random 
aggregates. In comparison, precursor 3 AK forms flexible fibers and the post-enzymatic product, 
3 A, forms ordered rigid -sheet fibers. Enzyme-triggered fibers which form on or near the cell 
surface of cancer cells that produce the enzyme stimuli are known to be cytotoxic to the cells.44 
Likewise, the observed decrease in viability of Caki-1 cells treated with 3 AK is most likely due 
to the formation of toxic anti-parallel -sheet nanofibers (3 A) that are selectively triggered to form 
by the overexpressed MMP-9 in the diseased cells.44 This effect is not observed in the control cell 




In conclusion, we have created a modular system of self-assembling peptide nanostructures 
to customize surface charge and supramolecular order to control enzyme kinetics and response 
action. These peptide nanostructures are bio-degradable and non-toxic, and after enzyme action, 
the non-assembling products remain non-toxic while the -sheet nanofiber forming products can 
selectively kill cancer cells. The kinetics of nanoparticles is important in biomedical applications 




profile, degradation rate of hydrogels, etc.). In addition, the morphology of the nanoparticles 
should be logically designed to achieve optimal function of the precursors (i.e. manipulation of 
cellular uptake, bio-distribution, etc.) and of the post-enzymatic product (i.e. biodegradability or 
therapeutic nanofiber/drug depots, etc.).  
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Solid Phase Peptide Synthesis (SPPS). Fluorenylmethyloxycarbonyl (Fmoc)-protected amino 
acids and pre-loaded Wang resins were purchased from Bachem. Peptides were synthesized on 
CEM Liberty Blue microwave assisted solid phase peptide synthesizer using ~1:5 resin to amino 
acid ratio and excess of diisopropylcarbodiimide (DIC), Oxyma 
(Ethyl(hydroxyimino)cyanoacetate), and 20% piperidine in dimethylformamide (DMF). The 
complete peptide-loaded resins were washed three times in dichloromethane, followed by three 
washes in diethyl ether on a filtration column.  The peptides were cleaved from the resins and side 
chain protecting groups were removed by reacting with TFA cocktail (95% trifluoroacetic acid, 




removing TFA cocktail, followed by precipitation in cold diethyl ether. Peptides were washed three 
times in cold diethyl ether, using centrifugation to collect the precipitated crude peptide. 
Preparatory High-Performance Liquid Chromatography (HPLC). Crude peptides were 
dissolved in 50% acetonitrile in water containing 0.1% TFA and purified through a preparatory C18 
column on the Thermo Scientific Dionex Ultimate 3000.  Acetonitrile was removed from the 
collected fragments on a rotary evaporator before lyophilization in MQ water or 10 mM HCl to 
remove residual TFA salts.  
TFA removal. Removing residual TFA salts is crucial for investigation of self-assembled peptide 
nanostructures. Chapter 4 will go over the issues that arise when residual TFA salts are ignored 
and a detailed procedure on how to remove them will be provided.   
High Resolution Mass Spectrometry (HRMS). HRMS data were obtained on an Agilent 6550 
QToF, with a dual sprayer ESI source, coupled to an Agilent 1290 Infinity LC system. Samples 
were analyzed by FIA (flow injection analysis) using a mobile phase of 50% acetonitrile in water 
(0.1% formic acid) with a flow rate of 0.4 mL/min.  
1H Nuclear Magnetic Resonance (NMR) Spectroscopy. Spectra were recorded on a Bruker 
AV400 at 400 MHz. Chemical shifts (δ) are given in ppm using D2O as solvent.  
Critical Aggregation Concentration (CAC). The critical aggregation concentrations of the 
precursor peptides were determined using pyrene as a fluorescent probe (Figure 2 and Table 2). 
Briefly, 1 mM of peptides were prepared in PBS and the pH was adjusted to 7.4 using 0.5 M NaOH 
or 0.5 M HCl prior to serial dilution in PBS with thorough vortexing. Peptide solutions were 
incubated at 50C for 15 minutes, then 2 L of stock pyrene solution (100 M in methanol) was 
added to 100 L of each peptide solution, gently mixed, and incubated for 5 minutes at 50C, then 




Pyrene emission spectra were measured from 350-450 nm (ex = 310 nm) in a micro fluorescence 
cuvette (3 mm path length) on Jasco FP-8500 Spectrofluorometer (measurement parameter: 20 nm 
excitation and 1nm emission bandwidth, 0.2 sec response, medium sensitivity, 0.2 cm-1 data 
interval, at 200 nm/min). The CAC was determined by plotting the ratio between intensities of the 
3rd to 1st peak of the pyrene emission spectra (Figure S25-26). Increasing peptide concentrations 
were measured in 0.1 mM increments until the slope of the plot had changed, and simultaneously 
the 3rd peak shifted from 382.4 nm to 384.4 nm and the 1st peak shifted from 371.8 nm to 373.4 
nm.  
ζ-potential. Measurements were made using an Anton Paar Litesizer 500 Particle Analyzer. 5 mM 
of peptide samples were prepared in 2% PBS and the pH was adjusted to 7.4 using dilute NaOH 
and HCl. 50 µL of samples were pipetted into Univette low volume cuvette and three series of 
measurements were taken at 25C using Smoluchowski approximation.  
Fourier Transform Infrared Spectroscopy (FTIR). Absorbance spectra were taken from 4000 
cm-1 to 800 cm-1 with 64 scans at 4 cm-1 resolution on the Bruker Vertex 70 spectrometer. 20 mM 
peptide solutions were prepared in deuterated phosphate buffer (pH = 8), pH was adjusted to 7.4 
using 0.5 M NaOH or 0.5 M HCl and sonicated for 10 min. 5 L of sample solutions were drop 
casted between two CaF2 cells with PTFE spacers (12 m thickness x 13 mm diameter). For 
analysis, deuterated phosphate buffer absorbance spectrum was subtracted from the sample 
absorbance and spectra were normalized from 1560 to 1655 cm-1. 
Atomic Force Microscopy (AFM). Images were taken on Bruker Dimension FastScan using 
FASTSCAN-B tip on fast scan mode. 1 mM of peptide solution was prepared in phosphate buffer 
(pH 7.4), sonicated for 10 min and drop casted on freshly cleaved mica and allowed to dry for 48 




Transmission Electron Microscopy (TEM). TEM images were taken on FEI Titan Halo 80-300 
microscope. 1 mM of peptide solution was prepared in 10 mM phosphate buffer (pH 7.4) sonicated 
for 10 min and 5 L of the solution was drop casted on a carbon film grid (400 mesh, copper) and 
dried completely. To the dry grid, 5 L of MilliQ water was drop casted and quickly blotted to 
wash away the phosphate salts and dried completely. Finally, 5 L of methylamine vanadate based 
negative stain (NanoVan® by Nanoprobes) was drop casted, blotted away, and dried completely.   
Cell lines. Human clear cell renal cell carcinoma line Caki-1 was newly obtained for these studies 
from the American Type Culture Collection (ATCC) (Manassas, Virginia, USA) and cultured in 
Roswell Park Memorial Institute (RPMI-1640) (Mediatech Inc., Manassas, VA) media containing 
10% Fetal Bovine Serum, certified, heat inactivated, US origin (FBS) (Gibco, Life Technologies, 
US), 1% Minimum Essential Media (MEM) nonessential amino acids (NEAA, Mediatech) and 
1% penicillin–streptomycin (PenStrep, Mediatech). IMR90 (human fetal lung fibroblast) cells 
were purchased from ATCC (Manassas, Virginia, USA) and maintained in Dulbecco's modified 
Eagle's medium (DMEM) (Mediatech) supplemented with 10% FBS, 1% NEAA and 1% Penicillin 
Streptomycin. 
Cell viability assay. Human fetal lung fibroblast (IMR90) and human clear cell renal cell 
carcinoma cells (Caki-1) were seeded in 96-well flat bottom microplate (BioLite Microwell Plate, 
Fisher Scientific, Waltham, MA). For IMR90 we used 6.0 X 103 cell per well and for Caki-1 we 
used 5.6 X 103 cells per well in 90μL of complete phenol red free cell culture media. The cells 
were allowed to grow for 24hours at 37°C and 5% CO2 in a humidified incubator. 10mM peptide 
solutions were prepared in phosphate buffer saline, pH adjusted to 7.4 using NaOH or HCl and 
sonicated for 10minutes.  Then 10μL of each sample was added into wells containing 90μL of 




hours at 37°C under 5% CO2. After each period of incubation, Presto Blue (Life Technologies, 
Carlsbad, CA) was used as an indicator of cellular toxicity; 11μL of presto blue was added to each 
well and incubated for 1 hours at 37°C under 5% CO2. The 96-wells plate was then analyzed using 
a multi-mode plate-reader BioTek Microplate Reader (BioTek U.S., Winooski, VT) at 530nm and 
590nm wavelength. The percentage of surviving cells was calculated as a normalized ratio of the 
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3.11. Supplementary Information 
 
 







Figure S2. HR-MS spectra of peptides 1 PK/PD. 
 
 









































Figure S11. 1H NMR spectra of 1 AD. 
 
 





Figure S13. 1H NMR spectra of 1 PD. 
 
 





Figure S15. 1H NMR spectra of 2 AD. 
 
 





Figure S17. 1H NMR spectra of 2 PD. 
 
 





Figure S19. 1H NMR spectra of 3 AD. 
 
 





Figure S21. 1H NMR spectra of 3 PD. 
 
 





Figure S24. 1H NMR spectra of 1 P. 
 
 





Figure S24. 1H NMR spectra of 2 P. 
 
 





Figure S24. 1H NMR spectra of 3 P. 
 





Figure S26. CAC of 1-3 AD and 1-3 PD. 
 
 





Figure S28. Triplicate measurements of ζ-potentials of 1 PK/PD. 
 





Figure S30. Triplicate measurements of ζ-potentials of 2 PK/PD. 
 













Figure S33. AFM images of 1-3AK/PK. Scale bar 500 nm. 
 




Table S1. FTIR absorbance of 1-3 AK/AD, 1-3 PK/PD, and 1-3 A/P in the amide I region. 
 
Table S2. The enzymatic products were identified and quantified for two separate trials. Column 
‘# K/D’ lists the MW of the 12 peptides and column ‘P6-P1’ lists the MW of the N termini portion 






Figure S35. LCMS spectra of 1 AK in A) first and B) second separate trials. 
 
Figure S36. LCMS spectra of 1 AD in A) first and B) second separate trials. 
 





Figure S38. LCMS spectra of 1 PD in A) first and B) second separate trials. 
 
Figure S39. LCMS spectra of 2 AK in A) first and B) second separate trials. 
 





Figure S41. LCMS spectra of 2 PK in A) first and B) second separate trials. 
 
Figure S42. LCMS spectra of 2 PD in A) first and B) second separate trials. 
 





Figure S44. LCMS spectra of 3 AD in A) first and B) second separate trials. 
 
Figure S45. LCMS spectra of 3 PK in A) first and B) second separate trials. 
 









Trifluoroacetic acid (TFA), as the reagent of post synthesis cleavage of peptides from solid 
phase, is commonly present in peptide products and is often ignored as an inert impurity. We 
demonstrate that TFA forms stable adducts with amine groups of the peptides in water. These 
adducts remain in place during aqueous solution and they can inhibit or otherwise influence the 
self-assembly of peptide nanostructures by disrupting the intermolecular ionic and hydrogen 
bonds. Using a peptide sequence which self-assembles to form nanostructures that are responsive 
to MMP-9, we characterized and compared the self-assembly behavior of the peptide with different 
concentrations of trifluoroacetate (TFAc) salts using 19F NMR, FTIR, AFM, TEM, critical 
aggregation concentration assay, and ζ-potential. We show that TFAc dramatically alters the 
morphology and properties of peptide nanostructures, which can lead to inconsistent 
characterization and biological study results between batches of peptides containing different 












Self-assembling peptides are versatile in their chemical composition and provide an 
excellent platform to design stable nanostructures such as micelles used in drug delivery or fibers 
that form hydrogels for 3D cell culture.1 Using commercially available amino acids, any desired 
peptide sequence can be readily synthesized due to the well-established solid phase peptide 
synthesis (SPPS) procedure developed by Merrifield, who won the Nobel Prize in Chemistry in 
1984.2 Most common methods of SPPS use trifluoroacetic acid (TFA) in the final step to remove 
the peptide product from the solid resin and to cleave acid labile bonds such as the protecting 
groups on the side chains of the amino acids (ex. lysine-Boc).3 However, the disadvantage of using 
TFA is that it is difficult to remove due to the stability of the adducts formed. As a result, residual 
trifluoroacetate (TFAc) often remains in the final peptide products, even in commercial 
preparations that are sold as TFA free. In academic studies on peptide self-assembly, traces of TFA 
are often ignored or they can lead to misinterpretation as part of the peptide characterization.   
The impact of TFA is especially profound when the peptides are used to create 
nanostructures by supramolecular self-assembly. It can change the molecular properties of the 
peptide mainly by forming adducts with amine groups of the peptides that play key roles in 
formation of hydrogen bonds or electrostatic interactions critical for self-assembly. Directly or 
indirectly, the blocking of amine groups may impact the driving forces of peptide self-assembly 
including electrostatic, hydrogen bonding, and cation-pi interactions. Specifically, the TFAc ion 
can block positively charged functional groups from interacting with negatively charged residues, 
as well as preventing formation of salt bridges between C and N termini that stabilize self-




Previously, our group has characterized Fmoc-FF peptide fibers co-assembled with Fmoc-
RGD that form hydrogels and can be used as 3D-scaffolds for anchorage-dependent cells.4 Fmoc-
FF self-assembles into β-sheets and showed a broad negative peak at 218 nm in CD and strong 
absorbance at 1630 and 1690 cm-1 in FTIR spectra. Fmoc-RGD showed weak signals in both 
analysis and a broad peak at 1655 cm-1 in FTIR, indicative of random coil arrangements. Thus, by 
incorporating less or more % of Fmoc-RGD to Fmoc-FF fibers, the stiffness of the hydrogel was 
controlled. Shortly after, Hamley et al. reported contradicting findings in which Fmoc-RGD could 
self-assemble into β-sheets and form stable hydrogels by itself.5 However, as acknowledged by 
the authors, this Fmoc-RGD contained high amounts of TFA, as clearly shown by the large 1673 
cm-1 absorbance peak detected in FTIR. In contrast, the Fmoc-RGD used in our study did not 
absorb at 1672 cm-1 in FTIR analysis. The authors compared the similar hydrogel dynamic elastic 
shear moduli of their Fmoc-RGD hydrogel to their previously studied Fmoc-KLV(Boc) hydrogel, 
emphasizing that this Lys residue is capped by a Boc protecting group, whereas Fmoc-RGD 
contains uncapped Arg residue. In this case, the authors failed to realize that the high 
concentrations of TFA acted like a protecting group on the Arg residue and formed hydrogels 
similar to Fmoc-KLV(Boc), which resulted in completely different morphology from the 
previously reported TFA free Fmoc-RGD. 
Here we use a model peptide sequence with 3 amine groups, FFGALGLKGK, which was 
previously described in Chapter 4 to form matrix metalloproteinase-9 (MMP-9) responsive 
nanocarrier for biomedical applications. Full description of peptide FFGALGLKGK can be found 
in Chapter 4 as peptide 2 AK. We report that residual TFAc salts in the peptide product 
significantly changes the self-assembly behavior of peptides using 19F NMR, FTIR, AFM, TEM, 




concentration, and morphology. Lastly, we demonstrate how the changes in the nanostructure 
properties can also affect biological studies, such as a delay in enzyme hydrolysis rates, and 
ultimately cause irreproducibility in experiments. 
 
4.2. Method development for washing TFA  
 
A self-assembling peptide sequence, FFGALGLKGK, that was previously characterized 
(Chapter 4) was used to demonstrate the significance of TFAc salt presence in self-assembly. 
During our investigation, a surprising amount of residual TFA was found in batches of peptide 
products. Peptides were synthesized using standard Fmoc-based SPPS, purified by prepHPLC on 
a C18 column using increasing gradient of acetonitrile with 0.1% TFA or 0.1% acetic acid against 
water with 0.1% TFA or 0.1% acetic acid, respectively. Purified peptides were lyophilized in water 
1-3 times before being characterized by LC-MS (Figure S3 in Chapter 4), 1H NMR (Figure S14 in 
Chapter 4), 19F NMR, and FTIR. Lyophilized peptides were dissolved in D2O and TFA 
concentration was quantified using 19F NMR.  
 
Figure 4.1. (A) Chemical structure of the proposed trifluoroacetate salt adducts formed with the 
amine groups of peptide FFGALGLKGK. (B) 19F NMR spectra of 1mM peptide in D2O, and 1mM 




For peptides purified on the prepHPLC with 0.1% TFA containing solvents, 3.04 mM of 
TFA was found per 1 mM of peptide, suggesting that TFA forms molar equivalent TFAc salts with 
the 3 amine groups of the peptide (Figure 1). For peptides that were purified using 0.1% acetic 
acid containing solvents, 0.39 mM of TFA was found per 1 mM of peptide, indicating that acetic 
acid can displace some of the TFAc salts. However, acetate salts could also alter self-assembly of 
peptides and quantification of acetate salt adducts formed with the peptide would require 1H NMR 
which is more challenging to analyze than 19F NMR. Therefore, we continued this investigation 
with peptides that were purified on prepHPLC with 0.1% TFA containing solvents. The 1:1 molar 
ratio of amine to TFA was also observed in peptide GPKGLRGD that contains 3 amine groups, 
and 2.91 mM TFA per 1 mM peptide was observed (data not shown).  
 
4.2.1. Washing 20 mM peptide in 10 mM HCl 
 
The TFAc were removed based on a modified protocol using HCl and verified by 19F NMR 
and FTIR.6  10 mM HCl solution was chosen to assure peptide stability and personal safety while 
handling large volumes of acidic solution.6  Briefly, lyophilized peptide was dissolved in aqueous 
10 mM HCl solution to prepare a 20 mM peptide solution (about 20 mg/mL). The solution was 
vortexed thoroughly at room temperature to allow protonation of the TFAc salts followed by 
removal of solvent by vaporization or lyophilization to complete the first round of TFA removal 
or “wash”. The procedure was repeated 1-4 times and peptides were subsequently dissolved in 
D2O for 
19F NMR and FTIR analysis. The unknown TFA concentration was quantified using 19F 
NMR by integrating the area under the peak measured against 1 mM of TFA in D2O (Figure 2A). 
After 4 rounds of washes, 113% molar equivalent TFA still remained which was also observed in 




that TFAc-amine salt adducts form strong ionic bonds which could not be displaced by water or 
dilute HCl.   
 
Figure 4.2. 20 mM peptide washed 0-4 times with 10 mM HCl solution. One round of wash 
indicates dissolving peptides in 10 mM HCl aqueous solution followed by removal of the solvent. 
(A) 19F NMR spectra of 1 mM peptide dissolved in D2O show % of TFA per peptide molar ratio. 
(B) Normalized FTIR spectra of 20 mM peptide dissolved in deuterated buffer (pH 7.4) show the 
absorbance of carbonyl peak of TFA at 1672 cm-1. 
 
4.2.2. Washing 1 mM peptide in 10 mM HCl 
 
In order to displace the TFAc with chloride ion, a large excess of HCl to peptide-TFA ratio 
was required. Therefore, the peptide concentration was decreased to 1 mM (about 1 mg/mL) 
instead of increasing the HCl concentration to avoid destabilization of the peptide and corrosion 
of lab equipment. The 19F NMR spectra show significant decrease in TFA concentration after one 
wash, from over 300% molar ratio to 9.3%, and after 3 rounds of washes only 1.6% TFA remained 
(Figure 3A). On the contrary, the TFA carbonyl peak at 1672 cm-1 was undetectable on FTIR after 




mM TFA being the lower limit for FTIR (Figure 2B, 4th wash) and 0.0003 mM TFA for 19F NMR 
(data not shown).  
 
 
Figure 4.3. 1 mM peptide washed 0-3 times with 10 mM HCl solution. One round of wash 
indicates dissolving peptides in 10 mM HCl aqueous solution followed by removal of the solvent. 
(A) 19F NMR spectra of 1 mM peptide dissolved in D2O show % of TFA per peptide molar ratio. 
(B) Normalized FTIR spectra of 20 mM peptide dissolved in deuterated buffer (pH 7.4) show the 
absorbance of carbonyl peak of TFA at 1672 cm-1. 
 
4.3. TFAc adducts alter peptide self-assembly 
 
Peptides were washed using 1 mM peptide in 10 mM HCl method and the TFA 
concentration was quantified by 19F NMR. The washed and unwashed peptides were characterized 
using FTIR, analysis of CAC, and MD simulations to study the self-assembly behavior, TEM and 
AFM to compare morphology, and ζ-potential analysis to measure the surface charge potential. 




4.3.1. Disruption of intermolecular peptide bonds  
 
The FTIR spectrum of unwashed peptide shows the characteristic TFA carbonyl peak at 
1672 cm-1 (Figure 3) which disappears after the first wash. This peak directly overlaps with the 
absorbance of peptide amide I band, which originates mainly from the C=O stretching of the 
peptide and typically consists of a series of overlapping components bands, making it difficult to 
accurately analyze the secondary structure without manipulating the data to subtract the TFA 
contribution.7 However, we found that the presence of the TFAc physically changes the 
supramolecular organization of the peptides, therefore, deriving the structure conformation 
information by subtracting the TFA absorbance signal would be inappropriate for our system.  
In order to resolve the individual components of the amide I band profile, curve fitting 
analysis was performed and the best fit was achieved using the Levenberg Maquardt algorithm. 
The spectral analysis of the unwashed peptide shows absorbance at 1678 and 1646 cm-1 (Figure 
4A), whereas the washed peptides show peaks at 1666 and 1632 cm-1 which can be identified as 
β-sheets, a strong peak centered at 1652 cm-1 that is exhibited by α-helices, and another peak at 
1642 cm-1 that can be attributed to random coil arrangement of the peptide (Figure 4B). The 
complete absence of 1672 cm-1 that is attributed to the TFA band confirms that TFA removal was 
successful. The curve fitting analysis suggests that the TFAc interacts with the cationic amine 
groups which hinders salt bridge formation and alters peptide back bone interactions and changes 
the self-assembly behavior. Consequently, it was important for us to chemically remove the TFAc 





Figure 4.4. Curve fitted FTIR of amide I region of unwashed (A) and washed (B) peptides after 
subtracting the D2O background. (A) Unwashed peptides absorb at 1678 and 1646 cm
-1 and (B) 
washed peptides absorb at 1666, 1652, 1642, 1632 cm-1, demonstrating that the hydrogen bonding 
pattern of the peptides are altered by presence of TFAc salts. 
 
4.3.2. Induced aggregation of peptide nanostructures 
 
Both TEM and AFM techniques show that the peptide with minimal amount of TFA self-
assembles into individual fibers rather than bundles of fibers. For peptides containing 0.03% TFA, 
discrete nanofibers about 5 nm in diameter were found evenly across the TEM grid (Figure 5A). 
For peptides with 1.6% TFA, uniform sample of individual fibers were observed on the mica for 
AFM (Figure 6A). On the contrary, peptides with 113% TFA formed indistinguishable fiber-like 
aggregates (Figure 6B). Unwashed peptides containing 304% TFA dried in a fractal-like pattern 
on the TEM grid (Figure 5B). This fractal pattern was also observed in AFM images of different 
peptide sequences which caused an overall major challenge in imaging dried samples of peptide 
nanostructures.  The aggregation of the peptide structures is likely due to TFA which forms ionic 






Figure 4.5. (A) TEM images of 1 mM peptide containing 0.03% TFA self-assembled into 
individual fibers of ~5 nm diameter. Scale bar 200 nm. (B) The same peptide with 304% TFA 
forms aggregates and dried in a fractal pattern.  Scale bar 1 µm. 
 
 
Figure 4.6. (A) AFM images of 1 mM peptide containing 1.6% TFA also self-assembles into 
discreet fibers. Scale bar 500 nm. (B) Peptides with 113% TFA forms aggregated fibers. Scale bar 
200 nm. 
Computational simulation using MARTINI8,9 coarse grain model agrees with the TEM and 
AFM images and predicts that the peptide self-assembles into a network of thin, individual fibers, 
each 3.5 nm in diameter, instead of forming thicker fiber bundles (Figure 7). The cross section of 
the fiber shows the hydrophobic Phe residues (orange) are buried in the core of the fiber. The 
cationic Lys residues (blue) decorate the fiber surface, thereby facing the water (Figure 7B). The 
chloride ions that are represented in yellow form weak ionic bonds with Lys in water and the fibers 
are still able to repel each other. However, if those anions are replaced with TFA, which can form 
stable salt adducts with Lys residues in water, the positive charges are screened causing the fibers 





Figure 4.7. 500 ns simulation of (A-B) 30 mM and (C) 60 mM FFGALGLKGK in 12.5 nm3 water 
box neutralized with 60 molecules of chloride, at 298°K and 1 bar. Phe residues are colored purple, 
Lys residues are blue, Gly residues are grey, Ala and Leu residues are orange and chloride salts 
are colored yellow.  
 
4.3.3. Decrease in positive charges and increase in hydrophobicity  
 
To confirm the decrease in positive charges of the peptide, ζ-potential analysis of the 
unwashed and washed peptides was performed (Table 1). The ζ-potential was negative for 
peptides containing 40-300% TFA. The negative ζ-potential is likely due to the free carboxylic 
group of the peptide which gives the peptide molecule a net charge of -1 if all of the amine groups 
are blocked by TFAc (in the case of 304% TFA) and becomes more positive as TFAc ions get 
displaced by chloride ions during the 10 mM HCl washes. Finally, the ζ-potential of the washed 
peptides increases to 2.2  0.5 mV which is comparable for the reported ζ-potential of 8.2  2.8 









Table 4.1. ζ-potential of 5 mM peptides in 2% PBS (pH 7.4) at 25C. 
 
Next, we investigated the CAC of the unwashed and washed peptides using pyrene as a 
solvatochromatic fluorophore. The 3:1 ratio which represents the hydrophobicity of the pyrene’s 
environment is overall higher for the unwashed peptides with 304% TFA. This is likely due to the 
TFAc adduct on the amine group of the N terminus which makes the diphenylalanine hydrophobic 
core more lipophilic. Unexpectedly, the CAC of unwashed peptide increases to 0.5 mM in 
comparison to the true value of 0.4 mM. Although the peptide is overall more hydrophobic with 
TFAc adducts, the amphiphilicity of the peptide decreases when the hydrophobic TFAc binds to 
the hydrophilic side. This change in the amphiphilic balance most likely causes the CAC to 
increase, since now the main driving force is hydrophobic aggregation.  
 
Figure 4.8. CAC of washed peptide (304% TFA) and unwashed peptide (0.03%TFA) determined 




4.3.4. Delays MMP-9-responsiveness  
 
Lastly, we compared the MMP-9 hydrolysis rate of washed and unwashed peptide. 
Previously, we have demonstrated that self-assembled nanostructures and the enzyme of interest 
should be oppositely charged in order to optimize enzyme engagement through short-range 
electrostatic interaction, and that highly ordered structures can hinder the enzyme’s accessibility 
to the substrate. Here we observed that the hydrolysis of unwashed peptide is delayed compared 
to the washed peptide (Figure 9).   
 
Figure 4.9. 1 mM of washed peptide (1.6% TFA) and unwashed peptide (304% TFA) incubated 





We have demonstrated that the presence of residual TFAc significantly alters properties of 
peptide nanostructures. TFA forms strong ionic bonds with the amine groups of the peptides in 1:1 
molar ratio, which cannot be removed by lyophilization in water. This leads to large molar excess 




on the N-terminus. In our system, the presence of TFA leads to a decrease in intermolecular 
hydrogen and electrostatic interactions, which prevented fiber formation, increased the CAC, 
rendered the ζ-potential negative, and delayed the hydrolysis of the peptide by MMP-9. Although 
removing TFA can be a tedious and arduous task, having unknown concentrations of TFA in 
different batches of peptides will lead to different self-assembly behavior and inevitably produce 
irreproducible results as exemplified here and in literature.4,5 Especially in biomedical 
applications, reproducibility of both morphology and size is crucial for translating the system for 
potential use in clinical and commercial application. In addition, the residual TFA may cause 
unanticipated cytotoxicity in biological assays. It is also worth noting that even commercial 
peptides which costs extra for TFA removal were still found to contain TFA (data not shown). 
Therefore, quantifying the amount of TFA present in a peptide batch by 19F-NMR and, if 
necessary, removing residual TFA from the final peptide product should be implemented in the 
general protocol for peptide synthesis. At the very least, the concentration of TFA should be 
consistent in different peptide batches in order to reproduce the desired experimental results. 
Finally, we encourage the readers to follow the protocol outlined in Supporting Information for a 
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4.6. Methods  
 
Solid Phase Peptide Synthesis (SPPS). Fluorenylmethyloxycarbonyl (Fmoc)-protected amino 
acids and pre-loaded Wang resins were purchased from Bachem. Peptides were synthesized on 
CEM Liberty Blue microwave assisted solid phase peptide synthesizer using ~1:5 resin to amino 
acid ratio and excess of diisopropylcarbodiimide (DIC), Oxyma 
(Ethyl(hydroxyimino)cyanoacetate), and 20% piperidine in dimethylformamide (DMF). The 
complete peptide-loaded resins were washed three times in dichloromethane, followed by three 
washes in diethyl ether on a filtration column.  The peptides were cleaved from the resins and side 
chain protecting groups were removed by reacting with TFA cocktail (95% trifluoroacetic acid, 
2.5% triisopropyl silane, and 2.5% water) for 2 h. The cleaved peptides were recovered by 
removing TFA cocktail, followed by precipitation in cold diethyl ether. Peptides were washed three 
times in cold diethyl ether, using centrifugation to collect the precipitated crude peptide. 
Preparatory High-Performance Liquid Chromatography (HPLC). Crude peptides were 
dissolved in 5% acetonitrile in water containing 0.1% TFA or 0.1% acetic acid and purified through 
a preparatory C18 column on the Thermo Scientific Dionex Ultimate 3000 using 5-50% acetonitrile 
(+ 0.1% TFA or acetic acid) gradient in water (+ 0.1% TFA or acetic acid).   
19F NMR. Sample solutions were prepared by dissolving peptide powder into D2O. Peptide 
powder was prepared by washing 1 mM peptide 0-3 times with 10 mM HCl, or by washing 20 
mM peptide 0-4 times with 10 mM HCl. 500L of sample solutions (1 or 0.5 mM peptide) were 




700 MHz spectrometer equipped with a 5-mm QCI-F cryoprobe at a frequency of 658.79 MHz. 
All 19F spectra were acquired were acquired locked and at 25 °C. Typical 1D 19F NMR acquisition 
parameters were as follows: 8.0 ms pulse length (60° flip angle), 100 ppm sweep width (65,789 
Hz) centered at -80 ppm, 0.50 sec acquisition time, 2 sec relaxation delay time, and 256 scans (11 
min). 1D 19F NMR spectra were processed with 5 Hz exponential line broadening and visualized 
using TopSpin 3.5.  
Computational Simulation. The MARTINI force field8,9 was applied to model peptide self-
assembly using the GROMACS molecular dynamics package.10 This force field utilizes a 4-to-1 
atom:CG-bead mapping to represent protein backbone and side chains (and a 2-3:1 atom:CG-bead 
mapping for ring systems). A cubic box with 30 peptide molecules, placed randomly with a 
minimum distance of 3 Å between them, was solvated in standard MARTINI CG water (4 water 
molecules per bead) to a final concentration of approximately 30 mM. The resulting net charge 
was neutralized by adding 60 molecules of chloride to the box. A Berendsen thermostat and 
barostat were used to keep the temperature at 298K and pressure at 1 bar, respectively.11 The box 
was energy minimized using the steepest descent integrator and then equilibrated for 6.25x106 time 
steps of 20 fs. The total simulation time equates 125 ns, but due to the smoothness of the CG 
potentials, this roughly equates to an effective 500 ns of atomistic simulation time.12 
Fourier-Transform Infrared Spectroscopy (FTIR). Sample solutions were prepared by 
dissolving peptide powder into D2O using vortex followed by sonication at room temperature for 
10 min. Peptide powder was prepared by washing 1 mM peptide 0-3times with 10 mM HCl, or by 
washing 20 mM peptide 0-4 times with 10mM HCl. 10 L of sample solutions (20 mM peptide) 
were drop casted between two CaF2 cells with PTFE spacers (12 m thickness x 13 mm diameter). 




the Bruker Vertex 70 spectrometer. For analysis in Figures 2-3, D2O absorbance spectra was 
subtracted from the sample absorbance and graphed from 1550 to 1750 cm-1. For analysis in Figure 
4, curve fitting analysis was performed to resolve the individual components of the amide I band 
profile. Input parameters such as the estimated number of components bands, their positions and 
widths were selected.  To increase the digital resolution spectrum was post zerofilled by an 
additional factor of 8. The best fit was achieved with the Levenberg Maquardt algorithm with 
which yielded the lowest residual RMS error value of 0.000148. 
Transmission Electron Microscopy (TEM). TEM images were taken on FEI Titan Halo 80-300 
microscope. 1 mM of peptide solution was prepared in 10 mM phosphate buffer (pH 7.4) sonicated 
for 10 min and 5 L of the solution was drop casted on a carbon film grid (400 mesh, copper) and 
dried completely. To the dry grid, 5 L of MilliQ water was drop casted and quickly blotted to 
wash away the phosphate salts and dried completely. Finally, 5 L of methylamine vanadate based 
negative stain (NanoVan® by Nanoprobes) was drop casted, blotted away, and dried completely.   
Atomic Force Microscopy (AFM). Sample solutions were prepared by dissolving peptide powder 
into 10 mM phosphate buffer (pH 7.4) using vortex followed by sonication at room temperature 
for 10 min. Peptide powder was prepared by washing 1 mM peptide 3 times with 10 mM HCl 
(Figure 6A) or 20 mM peptide 4 times with 10 mM HCl (Figure 6B). 5 L of sample solutions 
were drop casted on freshly cleaved mica and allowed to dry for 48 h before imaging. AFM images 
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Despite the plethora of cancer treatments available, which include surgery, radiation, 
chemotherapeutics, targeted therapies, and immunotherapy, there will be an estimate of 0.6 million 
cancer deaths in US in 2019.1 In search for novel cancer chemotherapeutics, both organic and 
metal-based compounds are being developed and investigated. In the field of metallodrugs, the 
most widely used drug is cisplatin that has been used for treatment of cancer since the 1970’s. 
Cisplatin and the follow up drugs, carboplatin and oxaliplatin, have a long history of use in 
treatment of ovarian, testicular, bladder, head and neck, and non-small cell lung cancers for the 
past 40 years.2 Although popular in clinical use, their effectiveness is still hindered by many 
problems including poor solubility, quick clearance, a limited spectrum of activity, acquired or 
intrinsic resistance, and a lack of selectivity leading to high nephrotoxicity and crippling adverse 
side effects in patients.2 To overcome these shortcomings, new platinum(IV) pro-drugs such as 
ormaplatin, iproplatin, and satraplatin have undergone clinical trials but have not yet been 
approved by the US FDA.3  
Additionally, it is important to explore metallodrugs (denominated as unconventional) 
based on metals other than platinum which display modes of action4 that are different from 
cisplatin,5–7 as well as their effects in the immune system.8 Current efforts have also been focused 
on developing agents that can be photoactivated9 or delivery systems that may improve their 
pharmacological profiles.10  Examples of unconventional metallodrugs in phase I/II clinical trials 




photodynamic compound (TLD-1433) that was studied succesfully in Phase Ib clinical trials for 
non-muscle invasive bladder cancer and has now entered Phase II clinical trials.9 More recently, 
copper(II)-casiopeina and copper(I) (HydroCuP) compounds have entered Phase I clinical trials, 
and a gold based drug, auranofin, is being investigated to be repurposed for the treatment of 
leukemia, small lung and ovarian cancer.11-13 However, for all small molecule-based drugs, it is 
imperative that they reach the tumor sites and enter the cancer cells. In order to improve on the 
efficacy and selectivity of molecular drugs, formulations using nanomaterials have become 
increasingly popular.  
Nanomedicine takes advantage of its particle size (1-500nm) and surface properties to 
accumulate selectively in the tumor microenvironment through leaky blood vessels that causes the 
enhanced permeability and retention effect.14 This passive targeting mechanism is used by 
Lipoplatin, a liposomal formulation of cisplatin in phase III clinical trial, to prolong circulation 
lifetime and to increase tumor uptake of cisplatin.15 In addition to passive targeting, nanomedicine 
can be designed to actively target tumor cells using various endogenous stimuli such as pH, 
antibodies, integrins, and enzymes that are characteristic of cancer cells.16 Of the endogenous 
stimuli, the up-regulation of matrix metalloproteinases (MMPs) have been observed in almost all 
types of cancers, including ovarian cancer, and the roles of the enzymes have been associated to 
cancer invasion and metastasis.17–19 More details in passive and active targeting nanomaterials can 
be found in Chapter 2, and MMP-responsive nanomaterials can be found in Chapter 3. Therefore, 
MMP-9 is a suitable cancer specific bio-target and the enzyme action can be exploited to produce 






Using previously described MMP-9-responsive peptide nanostructures in Chapter 5, we 
have encapsulated unconventional metal-based compounds with high anti-cancer properties to 
create a novel metallodrug-loaded nanocarriers. This system will allow payloads to be selectively 
released in the tumor microenvironment where MMP-9 is overexpressed, while controlling the 
rate of drug release by controlling the kinetics of MMP-9 hydrolysis of the peptide nanocarriers. 
Upon MMP-9 cleavage, the nanocarriers will disassemble to release the payloads and biodegrade 
into amino acids (Figure 1).  
 
5.2. Design of metallodrug-loaded nanocarriers  
 
Our group at Brooklyn College is focused on studying metal-based compounds for kidney 
cancer for which renal cell carcinoma (RCC) constitutes the most common type. Currently there 
are no efficient treatment options for advanced stage and metastatic RCC, since pharmacological 
interventions such as chemotherapy, targeted therapy or immunotherapy are very limited and only 
improve survival rates in periods of 9 to 20 months. Our group has developed a number of metal-
based compounds that have demonstrated enormous potential as chemotherapeutics against renal, 
colorectal and prostate cancers (including mechanistic and in vivo studies). These compounds 
include bimetallic compounds that incorporate the gold(I) compounds containing phosphanes21–24 
or N-heterocyclic carbene ligands25–27  and a second metallic fragment being titanocenes or 
ruthenium(II)-arene based complexes (Ti-Au and Ru-Au compounds). Gold(I) compounds 
containing either phosphanes28 or N-heterocyclic carbenes29,30 are emergining as derivatives with 
enormous potential as chemotherapeutic agents. 
For this project, we chose two gold(I) compounds that contain N-heterocyclic carbenes that 




compounds are ([AuX(NHC)]); NHC = 1,3-dibenzyl-4,5-diphenylimidazol-2-ylidene NHC-Bn; X 
= Cl A; 1,3-diethyl-4,5,-diphenylimidazol-2-ylidene NHC-Et; X = Br B).31,32 These compounds 
contain 4,5-diarylimidazoles cores with well-known pharmacological properties.33 Compound A 
(described by Tacke et al.) and a variation with the 2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyl-
1’-thiolate showed very good activity against a wide range of human cancer cell lines from the 
NCI 60 cell line panel, and relevant tumor growth inhibition in vivo for a human clear cell renal 
carcinoma Caki-1 xenograft mice model.31,34,35 Compound B, described by Gust et al. in 2011, 
was found to be cytotoxic (low or sub-micromolar range) in breast and colon cancer cell lines.32  
 
 
Figure 5.1. Cartoon representation of cancer targeted release of metallodrugs (compounds A and 
B) from biodegradable MMP-9-responsive peptide nanocarriers. Chemical structures of N-









In addition, modifications of compounds A and B showed improved anti-cancer activities. 
We have coordinated the [Au(NHC)]+ fragments of compounds A and B to [Ti(Cp)2M] fragments 
through a dual linker (-OC(O)-p-C6H4-S-) containing both a carboxylate and a thiolate group.
47 
The new compounds have been efficacious in vitro against human clear-cell renal carcinoma Caki-
1 and human prostate PC3 cells while being apoptotic and inhibiting migration, inhibition of 
thioredoxin reductase (TrRx) and vascular endothelial growth factor (VEGF) in prostate PC3 
cancer cell lines.47 In another example, an antibody drug conjugate (ADC) of compound A with 
an engineered antibody (Thiomab LC-V2050) via cysteine conjugation, showed moderate 
improvement of anti-proliferative activity in HER2 positive breast cancer cell line, in comparison 
to the non-conjugated drug.21 
 
 
Figure 5.2. Chemical structures of peptide 1 PK and 1 PD, and cartoon representations and pre 
and post MMP-9 hydrolysis of peptide nanocarriers. 80% of 1 PK is cleaved by MMP-9 in 48 h 




Although compounds A and B show potential anti-cancer activity, both drugs are highly 
insoluble in water and DMSO which makes it difficult to treat cancer cells in vitro or to admister 
them as solutions in vivo. Therefore, we sought out to encapsulate compounds A and B in MMP-
9-responsive peptide nanocarriers to solubilize the compounds in phsyiological conditions which 
could potentially increase the efficacy of the drugs (Figure 1). As examined in Chapter 3, tumor 
tissues from patients with renal cell carcinoma show significantly higher expression of MMP-9 
mRNA, with increasingly higher expression in advanced tumor stages.36 We hypothesize that by 
encapsulating the metallodrugs, which are highly active against this type of cancer, we can control 
the spatial and temporal release of the compounds based on MMP-9 activity, and increase the 
selectivity of these compounds.   
For the nanocarriers, we chose self-assembling peptides 1 PK and 1 PD, previously 
described in Chapter 3, which form ~200 nm long bundles of worm-like micelles with a 
hydrophobic core and a cationic or anionic hydrophilic tail (Figure 2). Full characterization of the 
peptide nanostructures can be found in Chapter 3. The anionic nanostructure, 1 PD, was found to 
have slow response to MMP-9, due to the electrostatic repulsion between the anionic nanostructure 
and the negatively charged MMP-9. On the contrary, the analogous cationic nanostructure, 1 PK, 
readily engages with MMP-9 and is cleaved to become the enzymatic product, 1 P, which no 
longer forms a self-assembled nanostructure (Figure 3). Using 1 PK and 1 PD to encapsulated 
compounds A and B, we can investigate how the rate of MMP-9 responsiveness could effect the 







5.3. Encapsulation of metallodrugs  
 
The encapsulation efficiency of compounds A and B by peptide nanocarrier 1 PD was 
investigated. Metal based drugs are advantageous as cytotoxic payloads in nanomedicine because 
the metal element can be precisely quantified by inductively-coupled plasma optical emission 
spectrometry (ICP-OES) or atomic absorption spectrometry (AAS). To quantify the amount of 
compounds A and B, samples were digested in concentrated nitric acid prior to analysis. 
 
5.3.1. Digestion of gold-based compounds 
 
The concentrations of the compounds A and B were analyzed using ICP-OES at 242.8 nm 
and 267.6 nm and measured against calibration curve of 0.01 - 1 mg/L Au standard prepared in 
aqueous 5% HNO3. In order to detect the elemental gold, compounds A and B were digested in 
concentrated nitric acid prior to analysis. First, a stock solution of 0.05 mM compound B was 
prepared in acetonitrile and was refluxed in concentrated nitric acid for 15 min, 30 min, or 60 min 
at 100°C. The digested samples were diluted 200 times in 10% HCl (aq) solution to achieve final 
concentrations within the range of calibration curve in a total of 5% HNO3 and 10% HCl aqueous 
solution. The measured mg/l values were calculated into mM and multiplied by the dilution factor 
to compare to the stock solution (Table 1). Higher concentrations of Au was detected with longer 
refluxing times. After 1 h, 0.045 mM of Au was detected in comparison to the actual 0.05 mM that 
should have been measured. A second stock solution of 0.075 mM compound B was prepared in 
acetonitrile and refluxed for 2 h or heated until dryness. The refluxed sample was diluted in 10% 
HCl (aq) and the dry samples were dissolved in 5% HNO3 and 10% HCl acqueous solution and 
diluted 100 times. For both methods, the detected Au was near 0.075 mM, which suggests that 2 




compound A was also detected when digested until dryness. Moving forward, we decided to digest 
compounds A and B by heating it until dryness in order to minimize errors from losing volume 
during reflux that will lead to incorrect dilution factor. 
 
Table 5.1. ICP-OES analysis of 0.05 mM or 0.075 mM compound B refluxed in concentrated 
nitric acid at 100°C over time or heated until dryness. The reported concentrations of Au were 
measured at 267.6 nm and 242.8 nm, and multiplied by the dilution factor.  
 
 
5.3.2. Encapsulation efficacy of peptide nanocarriers 
 
 Next, the encapsulation efficiency of the compounds in peptide nanocarriers was 
investigated following the procedure described in Figure 3. Briefly, peptides were dissolved in 10 
mM phosphate buffer and the pH was adjusted to 7.4 using 0.5 mM HCl or NaOH to make 2 mM 
peptide solution. To the peptide solution, stock drug solution (prepared in acetonitrile) was added 
for a final concentration of 1 mM peptide and 100, 10, 1, or 0.1 µM of drug in 1:1 ratio of buffer 
and acetonitrile. The mixture was vortexed and sonicated for 20 min and dried to a film then 
suspended in phosphate buffer and sonicated for 20 min. The non-encapsulated, hydrophobic drug 
was separated from the suspended drug-loaded peptide nanocarriers by centrifugation and the 
supernatant was collected. The Au content in the supernatant was digested in concentrated nitric 
acid as described above, and analyzed by ICP-OES or AAS. The encapsulation efficiency of 




of 10 µM compounds A and B were encapsulated, respectively, whereas only 23% and 24% of 1 
µM compounds A and B were encapsulated. At 100 µM, 61% of compound A and 20% of 
compound B was encapsulated by 1 PD,  likely due to the higher hydrophobicity of compound A. 
 
 
Figure 5.3. Encapsulation of metallodrugs in peptide nanocarriers. Step 1) Prepare 2 mM peptide 
stock solution in 10 mM phosphate buffer and adjust the pH to 7.4 using 0.5 mM HCl or NaOH. 
Prepare 200, 20, 2, 0.2 M drug stock concentrations in acetonitrile. Step 2) In 1.5 mL centrifugal 
tubes, combine 100 L of aqueous peptide solution with 100 L of the drug stock solution for a 
final concentration of 1 mM peptide and 100, 10, 1, 0.1 M of drug in 1:1 ratio of buffer and 
acetonitrile. Vortex the mixture and sonicate for 20 min. Step 3) Remove solvents compeltely 
under pressure. Step 4) Add 200 L of 10 mM phosphate buffer to the dried film to suspend the 
peptide-drug mixture. Gently vortex the aquesous mixture and sonicate for 20 min. Step 5) 
Separate the non-encapsulated, hydrophobic drug from the suspended peptide-drug nanocarriers 







Table 5.2. Encapsulation efficiency of 1 mM 1 PD with compounds A and B. 
 
 
5.4. Molecular dynamic simulations 
 
 In order to investigate the interactions between the metallodrugs and the peptides, 
dynamic simulations were performed. The structures of compounds A and B were initially 
optimized by using a computational approach based on the framework of the density functional 
theory (DFT), which has been widely exploited in studying the properties and reactivity 
metallodrugs.37–40 DFT methods encompass a wide range of approximations that leads to the so-
called density functionals, usually defined as pure, hybrid and range-separated hybrid depending 
on the theoretical treatment of the electron cloud.41 Herein, we have used PBE0,42 that have 
previously demonstrated to provide reliable results for structural and reactive properties gold(I)-





Figure 5.4. Optimized structures for compounds A and B at the selected DFT level of theory 
(PBE0-D3/def2-SVP). Molecules are represented in ball and stick model. Color scheme: hydrogen 
in white, carbons in grey, nitrogen in blue, chloride in green, bromide in red and gold in yellow. 
 
Next, we assessed the interaction of the metallodrugs with peptides 1 PK/PD and 2 PK/PD 
for comparison. Peptides were built up with the Protein Preparation Wizard module implemented 
in Maestro45 and protonation states of all side chains were defined at pH 7 by using PROPKA 
3.1.46 As illustrated in Figure 2, (1) the resulting peptides are located at the vicinity of the 
metallodrug (3.5 angstroms of distance). Aiming to mimic the conditions in solution and accurately 
correct solvent effects, (2) the model system is embedded in box filled with water molecules. 
Sodium cations or chlorides anions were added to counterbalance the total electric charge in of the 
peptides. Additional sodium and chloride ions were added as well to reproduce the physiological 








Figure 5.5. We illustrate the main steps of the MD workflow: (1) the peptide-compound B model 
is built up; (2) the systems is embedded in a water box; (3) MD simulations run for 100 ns, where 
the evolution of atoms are monitored by plotting the root-mean-square deviation (RMSD); (4) the 
equilibrated peptide-compound pair is extracted from the trajectory for further quantum 
mechanical calculations. 
Four systems are simulated: compound B with the peptides 1 PK, 1 PD, 2 PK, and 2 PD 
(peptide sequences can be found in Table 3). In MD trajectories, the root-mean-square deviation 
(RMSD) of atomic positions can be used to assess the average distance between atoms during the 
simulation, that is, the stability of the system. As shown in Figure 7, the structure of compound B 
is fairly stable during the whole simulation (red line), with a change of less than 1 Å only form the 






inspection of Figure 7 reveals that the associated RMSD to peptides significantly increase during 
the first ns of the simulation, which quickly raised up to 10-12 Å. This is the logical consequence 
of the larger flexibility of peptides. However, such oscillations are attenuated after 2-5 ns. Indeed, 
although blue lines demonstrated that the peptides are more flexible during the whole simulations, 
the RMSD for peptides are restricted to 6±2 Å in the last part of the trajectory.  
 
 
Figure 5.6. Root-mean-square deviation (RMSD) of compound B with Peptides 1 PK/PD and 2 
PK/PD in angstroms. RMSD for the compound are plotted in red, and for peptides in blue. 
 
Our computational study is completed by extracting the compound B-peptide pairs from 
the trajectory to compute their interaction energies at DFT level (Table 3). It is worth stressing that 
compound B and 2 PK remains unbound at the end of the MD simulation, and consequently we 










 In conclusion, we have demonstrated a proof-of-concept in which peptide nanostructures 
can be used to encapsulate metallodrugs. The highest concentration of compounds A and B 
encapsulated by 1 PD are only about 60 and 20 µM. According to the computational studies, 1 PD 
should have the highest stability with compound B and we can expect the drug loading capacity 
of 1 PK and 2 PD to be lower and weakest with 2 PK. However, the IC50 values of these 
compounds are well below 20 µM and higher drug concentrations are not necessary. In addition, 
the compounds are completely soluble within the nanocarrier which could lead to even smaller 
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Atomic absorption spectroscopy (AAS). Digested samples were measured on a Perkin Elmer 
Analyst 800 using a transversely heated graphite furnace (THGA) system at 242.8 nm.  
Inductively coupled-plasma optical emission spectroscopy (ICP-OES). Digested samples were 
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6.1. Summary  
In this thesis, we have successfully demonstrated that peptide building blocks can be 
systematically modified to design MMP-responsive nanostructures. This approach allows control 
of the morphology and charge of the nanostructures with simple changes in the amino acid 
sequence, including the MMP-cleavable P6-P6’ positions. Through the systemic study discussed in 
Chapter 3, we validated parameters other than the P6-P6’ sequence which affect the rate of MMP-
responsiveness, such as the morphology and electrostatic charge of the nanostructures which can 
help achieve MMP specificity. In Chapter 2, we analyzed over 40 different systems described in 
the literature and found multiple examples that confirm our conclusion. In addition, the systematic 
approach to peptide design allows us to control the morphology of the post-enzymatically cleaved 
product, or the mode of response. We demonstrated that amyloid-like fiber forming products 
causes selective cytotoxicity to cells that overexpress MMPs and disintegrating products are non-
toxic and continues to degrade into amino acids. As discussed in Chapter 2, the modes of MMP-
responsiveness can influence multiple factors such as the rate of payload release and its efficacy. 
Lastly, we demonstrated that peptide nanostructures can be used to encapsulate anti-cancer 
organometallic compounds that are otherwise too hydrophobic to be administered in vitro or in 
vivo. During this investigation, it is imperative that the self-assembly of the peptide nanostructures 
are reproducible each time, which can be significantly altered by trace amounts of TFA salts that 
are left from peptide synthesis but are often neglected. Through a number of techniques, we 
demonstrated that peptide self-assembly is significantly altered by TFA which could explain the 




In summary, we have addressed the questions asked in the beginning of Chapter 1 through 
experimental results and literature analysis. As demonstrated in Chapters 2 and 3, specificity 
towards MMPs can be achieved by nanomaterials by 1) using optimized P6-P6’ sequence for the 
target MMP, 2) designing morphologies that are similar to the native substrate of the target MMP, 
and 3) by mis-matching the short-range electrostatic interaction of the MMP and nanomaterial. 
The three criteria can be readily modified in peptide nanostructures by small changes in amino 
acids, unlike other materials which require a different a different building block (ie. negatively 
charged phosphatidylglycerol vs. neutral phosphatidylethanolamine). 
Literature analysis showed that MMP-responsive nanomaterials can improve the efficacy 
of anti-cancer treatments based on the modes of response. The efficacy of the drugs loaded in 
MMP-responsive materials are not always improved by increasing toxicity or tumor reducing 
ability, but by making the treatment more selective and causing less systematic damage. We 
demonstrated that the modes of response can also be controlled using peptide nanostructures to 
form cytotoxic fibers or non-toxic products. In addition, we showed proof-of-concept in which 
peptide nanostructures can be used to encapsulate metallodrugs which can potentially increase the 
efficacy of these drugs by making them more soluble and selective towards cells that overexpress 
MMP.  
  
6.2. Future work 
 The work of MMP-responsive peptide nanostructures will carry on testing if the efficacy 
of the metallodrugs can be improved in vitro. Currently, we are characterizing drug-loaded peptide 
nanocarriers to study the stability of the nanocarrier and the rate of MMP-responsiveness and drug 




therapeutic effects. The in vitro studies will be conducted in cell lines with high and low expression 
of MMP-9 which will be quantified by ELISA. In addition, the stability of the peptides will be 
tested in human plasma which can help to predict the half-life of the drug-loaded peptide 
nanocarriers when administered in vivo. This work will continue as a joint-collaboration between 
the Contel group at Brooklyn College and the Ulijn group at ASRC.  
 Due to the versatility of the peptide nanostructures, and the highly disease relevant MMP 
target, many collaborative interests have sprung out from this research. For example, MMPs are 
expressed in mice with multiple sclerosis that break down the blood-brain-barrier. By treating the 
mice with one of AK peptides loaded with therapeutic payloads, the fibers can localize at the site 
of MMP overexpression and build up the blood-brain-barrier and simultaneously release the 
therapeutic agents. Other research groups have shown interest in modifying the terminal Phe to 
Tyr residue which can be used to conjugate radioactive iodine (131I) for diagnostic imaging. 
Another research group is interested in using the MMP-response peptides as capsules to 
encapsulate growth factors that can simulate cell differentiation. The possible applications of these 
MMP-responsive peptide nanostructures are enormous, and while they may not be successful for 
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